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Gram-negative bacteria decorate their outermost surface structure, lipopolysaccharide, 
with elaborate chemical moieties, which effectively disguises them from immune 
surveillance and protects them from the onslaught of host defenses. Many of these 
changes occur on the lipid A component of lipopolysaccharide, which is crucial for host 
recognition of Gram-negative infection. Despite its highly inflammatory nature, LPS is a 
molecule with remarkable therapeutic potential. Lipid A is a glycolipid that serves as the 
hydrophobic anchor of LPS and constitutes a potent ligand of the TLR4/MD2 receptor of 
the innate immune system. A less toxic mixture of mono-phosphorylated lipid A species 
(MPL) recently became the first new FDA-approved adjuvant in over 70 years. Whereas 
wild-type E. coli LPS provokes strong inflammatory MyD88-mediated TLR4 signaling, 
MPL preferentially induces less inflammatory TRIF-mediated responses. Here, we 
developed a system for combinatorial structural diversification of E. coli lipid A yielding 
a spectrum of bioactive variants that display distinct TLR4 agonist activities and cytokine 
induction. Mice immunized with engineered lipid A/antigen emulsions exhibited robust 
IgG titers indicating the efficacy of these molecules as adjuvants. Other types of 
modification to the lipid A domain, such as altering the length of the fatty acyl chains that 
anchor LPS to the cell membrane, were found to affect bacterial fitness but not drastically 
influence detection by the TLR4/MD2 receptor. Overall, this combinatorial approach 
demonstrates how engineering lipid A can be exploited to generate a spectrum of 
immunostimulatory molecules for vaccine and therapeutics development as well as for a 
deeper understanding of bacterial membrane biogenesis.  
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Chapter 1: Introduction1 
This introductory chapter includes a description of lipid A and the regulatory 
mechanisms controlling lipid A modification along with a discussion of the impact that 
these modifications have on pathogenesis, bacterial physiology and bacterial interactions 
with the host immune system. This information is then followed by background for the 
engineering of lipid A for therapeutic use. 
1.1 REMODELING OF THE GRAM-NEGATIVE OUTER MEMBRANE  
1.1.1  The Gram-negative cell envelope. 
The bacterial cell envelope is a complex structure that protects the cell from the 
surrounding environment. A defining feature of Gram-negative bacteria is the presence of 
an outer membrane, which is an asymmetric bilayer with glycerophospholipids confined 
to the inner leaflet and lipopolysaccharide (LPS) anchored to the outer leaflet1 (Fig. 1a,b). 
Similarly to most cell envelope components, LPS is made at the cytoplasmic face of the 
inner membrane and must be transported across the two bilayers and periplasm to 
become integrated in the outer membrane1.  
                                                
1 Large portions of this chapter have been previously published. Needham, B. D. & Trent, 
M. S. Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. 
Nat. Rev. Microbiol. 11, 467–481 (2013). 
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Figure 1.1  The cell envelope of Gram-negative bacteria 
 (a) A cryotomography image of an E. coli cell shows characteristic inner and outer 
membranes (scale bar of 200 nm). (b) Schematic of the Gram-negative cell envelope 
illustrating the typical membrane composition, with the outer leaflet of the outer 
membrane being composed of lipopolysaccharide (LPS), anchored to the membrane by 
its lipid A domain.  Envelope components are abbreviated: outer membrane (OM), inner 
membrane (IM), and peptidoglycan (PG). (c) The lipid A and inner core (Kdo) portion of 
LPS can be extensively modified after synthesis of the β-1ʹ′,6-linked disaccharide of 
glucosamine that is both phosphorylated and fatty acylated (black). Modifications 
controlled by the PmrAB two-component system and the enzymes responsible in 
Salmonella spp. lipid A are displayed in red as follows: L-Ara4N (aminoarabinose) 
addition (ArnT), phosphoethanolamine addition (EptA) and phosphorylation (LpxT). 
Modifications controlled by the PhoPQ two-component system are indicated by blue as 
follows: phosphoethanolamine addition (EptB), deacylation (PagL) and acylation (PagP). 
Modifications enzymes not known to be controlled by a two-component system are 
indicated in green as follows: hydroxylation (LpxO) and deacylation (LpxR). LpxO 
transcription is modestly induced by PhoPQ but LpxO activity occurs independent of 
these two-component systems. 
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LPS is composed of three domains: a lipid A hydrophobic anchor, core 
oligosaccharide and O-antigen2 (Fig. 1b). Some organisms (for example, Neisseria spp.) 
produce lipooligosaccharide (LOS), in which the repeating O-antigen domain is absent 
and is replaced by an extended core region3. Lipid A, the endotoxic portion of LPS and 
the site for many LPS modifications, is initially synthesized as a β-1ʹ′,6-linked 
disaccharide of glucosamine that is both phosphorylated and fatty acylated (Fig. 1c). In 
some organisms, such as Escherichia coli K12, this structure represents the typical form 
of lipid A in the outer membrane. Lipid A biosynthesis is well-conserved across Gram-
negative bacteria and occurs via the nine-step enzymatic Raetz pathway2.  
  
 4 
Figure 1.2 Raetz pathway of lipid A biosynthesis in E. coli. 
Biosynthesis of the well-conserved, Kdo2-lipid A molecule via a nine-step enzymatic 
pathway in E. coli. The structures of biosynthetic intermediates are shown in black and 
labeled in blue. The enzyme names are shown in red. Particularly relevant to this work 
are the late acyltransferases, LpxL and LpxM, which will be discussed further in Chapter 
3.  
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Despite initial studies reporting that lipid A could be modified with polar 
substituents (such as amino sugars4), it was nevertheless viewed as a static structure. This 
view changed in the late 1990s following characterization of the lipid A biosynthesis 
pathway, which established a foundation for studies that discovered that lipid A is altered 
post-synthesis5–7. In fact, Gram-negative organisms have evolved several LPS 
modification strategies that allow them to adapt to their unpredictable and often hostile 
surroundings2.  During and after trafficking to the cell surface, lipid A can undergo 
extensive remodeling, resulting in the wide variety of lipid A structures that are observed 
across species. This is accomplished by diverse lipid A modification enzymes that 
remove or add acyl chains and phosphate groups, as well as other enzymes that transfer 
various constituents onto the molecule, such as sugars, phosphoryl containing groups and 
even an amino acid, all of which can influence bacterial interactions with the host  (Table 
1.1). Modifications also occur on other moieties of LPS but these non-lipid A 
modifications are not the focus of this work.  
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Table 1.1  Modifications to the Kdo-lipid A domain of LPS. 
 
Enzyme 
 
Protein localization 
(Active site topology) Pathogenic organisms* Activity 
Contributors to 
regulation Effect of Modification 
 
AlmG 
 
Inner membrane 
(Cytoplasmic) 
 
Vibrio 
 
Glycine transfer to hydroxyl 
group of 3' acyloxyacyl chain 
 
 
Unknown 
 
CAMP resistance 
ArnT (PmrK) 
 
Inner membrane 
(Periplasmic) 
E. coli, Salmonella, 
Shigella, Pseudomonas, 
Yersinia, Klebsiella, P. 
mirabilis, Burkholderia 
 
Aminoarabinose addition 
 
PmrAB 
ParRS, CprRS (P. 
aeruginosa) 
CAMP resistance 
 
EptA (LptA, 
PmrC)  
 
Inner membrane 
(Periplasmic) 
E. coli, Salmonella, Vibrio, 
Shigella,, Neisseria, 
Helicobacter 
Phosphoethanolamine 
addition 
 
PmrAB  CAMP resistance 
EptB Inner membrane 
(Periplasmic) 
E. coli, Salmonella, 
Yersinia 
Phosphoethanolamine 
transfer to Kdo 
 
PhoPQ, sRNA MgrR Modest CAMP 
resistance 
EptC Inner membrane 
(Periplasmic) 
Campylobacter Phosphoethanolamine 
transfer to lipid A, flagellar 
rod, and other substituents 
 
Present under normal 
laboratory conditions 
CAMP resistance, 
motility 
FlmF1 Inner membrane 
(Periplasmic) 
Francisella Glucose, mannose addition 
to lipid A 
 
Present under normal 
laboratory conditions 
Possible role in CAMP 
resistance 
 
FlmF2 Inner membrane 
(Periplasmic) 
Francisella Galactosamine addition to 
lipid A 
 
Present under normal 
laboratory conditions 
Possible role in CAMP 
resistance 
 
FlmK Inner membrane 
(Periplasmic) 
Francisella Glucose, mannose or 
galactosamine addition to 
lipid A 
Present under normal 
laboratory conditions 
Possible role in CAMP 
resistance, TLR4 
evasion 
 
KdkA Inner membrane 
(Cytoplasmic) 
Haemophillus, Bordetella, 
Vibrio, Pasteurella, 
Actinobacillus, Shewanella 
 
Phosphorylation of Kdo Present under normal 
laboratory conditions 
Possible effect on toxin 
delivery 
KdoH1, 
KdoH2 
(KdhA) 
 
Inner membrane 
(Cytoplasmic) 
Helicobacter, Francisella, 
Legionella 
Removal of outer Kdo Present under normal 
laboratory conditions 
CAMP Resistance 
 
KdoO Inner membrane,  
(Cytoplasmic) 
 
Burkhoderia, Yersinia, 
Acinetobacter 
 
Hydroxylation of Kdo Present under normal 
laboratory conditions 
Unknown 
LmtA Inner membrane 
(Cytoplasmic) 
 
Leptospira interrogans Methylation of lipid A Present under normal 
laboratory conditions 
Unknown 
 
LpxD2 Inner membrane 
(Cytoplasmic) 
Francisella 
 
Addition of shorter (C16) 
primary acyl chains to lipid A  
 
Cold temperature Increased membrane 
fluidity 
LpxE Inner membrane 
(Periplasmic) 
Francisella, Helicobacter, 
Porphyromonas, 
1-phosphatase Present under normal 
laboratory conditions 
CAMP resistance, 
TLR4 evasion 
 
LpxF Inner membrane 
(Periplasmic) 
Francisella, Helicobacter, 
Porphyromonas, 
Leptospira 
 
4'-phosphatase 
 
Present under normal 
laboratory conditions 
CAMP resistance, 
TLR4 evasion 
 
LpxO Inner membrane 
(Cytoplasmic) 
Salmonella, Klebsiella, 
Pseudomonas, Bordetella, 
Leigionella 
 
Hydroxylation of lipid A acyl 
chains 
Present under normal 
laboratory conditions 
Stress response 
coordination 
LpxP 
 
Inner membrane 
(Cytoplasmic) 
E. coli, Yersinia, 
Salmonella, Legionella 
 
Alternative biosynthetic 
acyltransferase in cold 
 
Cold temperature Membrane integrity 
and fluidity 
LpxR Outer membrane 
(Extracellular) 
Salmonella, E. coli 
0157:H7, Helicobacter, 
Vibrio, Yersinia 
 
3'-O-deacylase sRNA MicF, 
aminoaraminose lipid 
A modification 
TLR4 evasion 
LpxT Inner membrane 
(Periplasmic) 
E. coli, Salmonella, 
Yersinia 
 
Phosphorylation of lipid A, 
recycling of und-
pyrophosphate 
 
PmrAB, small peptide 
PmrR 
Unknown 
PagL Outer membrane 
(Extracellular) 
Salmonella, 
Pseudomonas, Bordetella, 
Burkholderia 
 
3-O-deacylase 
 
PhoPQ, 
aminoarabinose lipid A 
modification 
Lowered TLR4 
activation 
PagP Outer membrane 
(Extracellular) 
E.coli, Salmonella, 
Shigella, Yersinia, 
Bordetella, Legionella, 
Pseudomonas, Erwinia, 
Klebsiella 
 
Palmitate addition PhoPQ, membrane 
perturbation 
Selective CAMP 
resistance, membrane 
integrity 
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Lipid A alterations directly impact pathogenesis by changing outer membrane 
permeability, promoting resistance to antimicrobial peptides and interfering with the 
host’s ability to recognize LPS as a conserved microorganism-associated molecular 
pattern (MAMP)2,8. The diversity of LPS modification systems is quite extraordinary and 
the accumulated knowledge about these systems has provided deeper insight into 
bacterial mechanisms that contribute to human disease and immunity.  
1.1.2  Regulation of lipid A remodeling 
Lipid A modifications are often only necessary for a portion of the bacterial life 
cycle, such as host colonization, and as a consequence the enzymes responsible for the 
modifications are subject to both transcriptional and post-translational regulation. Many 
modification enzymes are embedded in the outer membrane in close proximity to lipid A, 
necessitating tight control for selective activity, while others are constitutively active 
regardless of their localization. Two-component systems, small RNAs (sRNAs), peptide 
feedback loops and substrate availability are all involved in directing the activity of these 
enzymes (Fig. 1.2). 
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Figure 1.3 Regulation of lipid A modification enzymes. 
Transcriptional (A) and post-translational (B) control is shown. Transcriptional control 
(A) includes gene regulation by two-component systems such as PhoPQ leading to 
acylation and deacylation of lipid A by the enzymes PagP and PagL, respectively, and 
PmrAB, leading to addition of aminoarabinose (L-Ara4N) and phosphoethanolamine 
(pEtN) by the enzymes ArnT and EptA, respectively. Expression of EptB, another pEtN 
transferase, is repressed by the small RNA (sRNA) MgrR, which is induced by PhoPQ. 
PhoPQ transcription is repressed by the sRNA, MicA. Post-translational control (B) 
includes inhibition of the kinase LpxT by the small peptide PmrR, which is upregulated 
by PmrAB in response to Fe3+ as part of a negative feedback loop that ultimately 
decreases the cell surface affinity for Fe3+ due to a less negatively charged lipid A. Also 
depicted in (B) is regulation by substrate availability. The acyltransferase PagP, the 
extracellular active site of which is normally separated from its phospholipid donor, is 
activated upon phospholipid displacement to the cell surface due to membrane 
perturbation. The deacylase LpxR is inhibited by the L-Ara4N lipid A modification, 
which is more prevalent in certain conditions (i.e. Y. enterocolitica at 21° C).  
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1.1.2.1 Transcriptional control 
Two-component systems are typically composed of a sensor kinase that is 
autophosphorylated upon stimulation and transfers its phosphate group to a response 
regulator that serves as a transcription factor.  To date, various two-component systems 
have been implicated in the regulation of lipid A modification enzymes, including the 
widespread PhoPQ and PmrAB systems, and the ParRS and CprRS systems in 
Pseudomonas aeruginosa9–14. Other systems, such as EvgAS, Rcs, and BvgAS, have been 
linked to the activity of the PhoPQ system or its downstream genes, but their direct 
involvement in the modification of lipid A has not yet been thoroughly investigated15–18.  
Functional PhoPQ systems are widespread among bacteria, with some variation in 
the activation signal used and the genes that are regulated11,19. Activation of the PhoPQ 
system in Salmonella spp. by acidic pH, certain antimicrobial peptides and the depletion 
of Mg2+ and Ca2+, stimulates transcription of pagP and pagL and subsequent upregulation 
of the encoded proteins, which palmitoylate and deacylate lipid A, respectively (Fig. 
1.1d, Fig. 1.2, Table 1)10,11,20–22. Furthermore, both of these enzymes are also subject to 
post-translational regulation (see below). Because the active sites of these two enzymes 
are found on the extracellular surface of the outer membrane, and in close proximity to 
lipid A, they require tight control to ensure that lipid A modification is appropriately 
regulated.  
In Salmonella spp. and E. coli (currently unpublished in E. coli), PhoPQ further 
influences lipid A modification by activating the PmrAB system (Fig. 1.2a), although in 
P. aeruginosa the two systems have not been shown to be coupled23. Direct activation of 
PmrAB in Salmonella spp. occurs upon sensing iron, aluminium and low pH, and leads to 
the upregulation of genes such as arnT (also known as pmrK) and eptA (also known as 
lptA and pmrC) that transfer 4-amino-4-deoxy-L-arabinose (L-Ara4N, abbr. 
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aminoarabinose) and phosphoethanolamine groups to lipid A, respectively12 (Fig. 1.1d, 
Fig. 1.2). Similar to Salmonella spp., the PmrAB system in P. aeruginosa is activated by 
the depletion of cations, such as Mg2+, but it is also activated by antimicrobial peptides24. 
In E. coli, Salmonella spp., P. aeruginosa and others, the activity of the enzymes 
controlled by PhoPQ and PmrAB strengthen the integrity of the outer membrane 
permeability barrier in the presence of antimicrobial peptides and depleted cations, which 
enhances bacterial survival in the host25,26.  
The ParRS and CprRS are independent two-component systems that have only 
been found in P. aeruginosa and respond to subinhibitory concentrations of antimicrobial 
peptides13,14. Thus, these systems might have an important role during infection. While 
both systems upregulate pmrA, pmrB and the genes responsible for aminoarabinose 
addition to lipid A, they are differentially activated in response to some antimicrobial 
peptides13,14. For instance, the synthetic peptide CP28 activates the CprRS system, 
whereas the ParRS system seems to be more responsive to the peptide indolicidin14. The 
two systems react similarly to other peptides such as polymyxin B and colistin, which are 
both used to treat P. aeruginosa infections14. P. aeruginosa is a useful, but complex, 
model pathogen for studying lipid A modification regulatory schemes because 
structurally divergent forms of lipid A are associated with different types of infection, 
including acute bronchiectasis lung infections and chronic colonization of the cystic 
fibrosis lung27. 
The PhoPQ system has also been shown to mediate modification of lipid A 
through transcriptional activation of non-coding sRNAs. Many sRNAs modulate the 
expression of outer membrane proteins28–30, but recently the MgrR sRNA of E. coli was 
shown to regulate lipid A modification31 (Fig. 1.2a). MgrR is a transcriptional target of 
PhoP and is conserved in E. coli and certain species of Citrobacter, Enterobacter and 
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Klebsiella31. It regulates various genes, including the negative regulation of eptB31, which 
encodes an enzyme that transfers phosphoethanolamine to the outer Kdo residue of LPS8 
(Fig. 1.1C). Although EptB activity results in a modest increase in resistance to the 
cationic antimicrobial peptide (CAMP) polymyxin B, it is unlikely that this is the main 
function of this enzyme because conditions that inhibit EptB simultaneously induce the 
other PhoPQ regulated genes, which confer higher CAMP resistance31. In addition to 
regulating an sRNA, the PhoPQ system itself is controlled by another sRNA (MicA) (Fig. 
1.2a) which inhibits translation of PhoP by competitive binding to the ribosome binding 
site of the PhoP mRNA32. MicF represents another example of an sRNA that interacts 
with lipid A modification enzymes. This sRNA binds to LpxR transcripts, which encode 
a lipid A deacylase (Table 1.1, Fig 1.1c), and increases degradation of the mRNA by 
exposing regions susceptible to RNase E, a major contributor to RNA turnover in many 
bacteria33.  
1.1.2.2 Post-translational control 
In addition to transcriptional regulation, lipid A modification enzymes are also 
subject to post-translational control mechanisms. For example, in Salmonella enterica 
serovar Typhimurium, the PmrAB system orchestrates a delayed negative feedback loop 
that can be activated by Fe3+ and allows initial uptake of the ion but sets in motion a shift 
in the cell surface charge that reduces Fe3+ retrieval from the extracellular environment. 
This feedback loop is established through PmrAB-induced expression of a short peptide, 
PmrR, which binds to and inhibits the lipid A modifying enzyme LpxT34 (Fig. 1.2b, Table 
1.1). LpxT phosphorylates lipid A (Fig. 1.1c) and thereby increases the overall net 
negative charge of the outer membrane. However, when LpxT activity is inhibited, other 
modifying enzymes are capable of transferring amine-containing constituents to lipid A35 
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and the outer membrane eventually becomes less negatively charged and has reduced 
affinity for Fe3+ 34. This mechanism regulates lipid A modifying enzymes such as LpxT 
and those transcriptionally induced by PmrAB (such as eptA and arnT), prevents the 
intracellular accumulation of toxic Fe3+ concentrations, and dampens PmrA-dependent 
transcription in a delayed manner as a result of the lowered affinity of PmrAB-activating 
Fe3+ at the membrane. Such feedback control of lipid A modification regulatory systems 
by small peptides might be a common theme. In fact, other small peptides such as SafA 
(in E. coli) and MgrB (in E. coli, S. Typhimurium and Y. pestis) are inner membrane 
peptides that interact with the periplasmic domain of PhoQ and activate or repress PhoQ 
activity, respectively36,37. 
Other post-translational control mechanisms rely on substrate availability.  
Although the acyltransferase PagP is transcriptionally upregulated by PhoPQ in 
organisms such as Salmonella spp. and E. coli, its activation is enhanced by 
environmental or intracellular membrane stress38. For example, in E. coli PagP remains 
dormant in the outer membrane under standard growth conditions. However, treatment 
with membrane perturbing agents, such as ethylenediaminetetraacetic acid (EDTA), 
results in the displacement of the phospholipid donor substrate of PagP from the inner to 
the outer leaflet of the outer membrane, placing it in close proximity of the PagP catalytic 
domain39. PagP cleaves the phospholipid substrate, restoring the composition of the outer 
membrane and increasing the integrity of the permeability barrier by further acylating 
lipid A40 (Fig. 1.2b).  
The affinity and activity of lipid A modification enzymes are also modulated by 
the chemical composition of lipid A. For example, in Yersinia enterocolitica, LpxR 
deacylates lipid A at 37° C but at 21° C, LpxR activity is impeded.  At 21° C, pmrAB and 
the genes necessary for aminoarabinose addition are induced and the elevated amounts of 
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aminoarabinose residues on lipid A seem to suppress LpxR activity41. In S. Typhimurium, 
PagL is similarly repressed by aminoarabinose-modified lipid A, although this effect 
seems to be temperature-independent22.  
These various forms of post-translational regulation afford quick response times 
for modification of the outer defense barrier, since the enzymes are already present and 
primed to function as soon as the appropriate signal is detected. Both transcriptional and 
post-translational regulation work together, sometimes as functionally redundant 
mechanisms, allowing Gram-negative bacteria to adapt to diverse environments and 
thereby ensure their survival. The diversity of regulatory mechanisms also illustrates the 
importance of lipid A structure as a major contributor to the membrane barrier.  
 
1.2 EFFECTS OF LIPID A REMODELING ON THE INNATE IMMUNE RESPONSE.  
1.2.1  Host defenses target lipid A 
Considering the intimate contact that humans have with bacteria, colonization 
with pathogenic Gram-negative bacteria is astonishingly low.  This is largely attributed to 
the formidable arsenal of host defenses that eliminate invading pathogens by recognizing 
and responding to highly-conserved components of infectious agents, known as 
microorganism-associated molecular patterns (MAMPs)42.  Because LPS is an essential 
component of the Gram-negative cell surface, it serves as an effective MAMP to trigger 
the innate immune system1,2.  The host offers a nutrient-rich but perilous environment for 
a bacterium. For example, intestinal colonization requires a bacterium to journey through 
the acidic pH of the stomach and encounter toxic compounds such as bile and 
antimicrobials during transit43, and the bloodstream is swarming with LPS-binding 
proteins, antibodies, complement and immune cells primed to detect LPS1,44–47.  Every 
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point of entry for a bacterium is well-defended, but since many of these protective 
mechanisms rely on lipid A detection, the modification of lipid A affords the bacterium 
an opportunity to evade the immune system and establish an infection. 
1.2.2  Charge-dependent binding of lipid A occurs in the host 
Charge-dependent binding of various host molecules (such as CAMPs, platelet 
factor 4 (PF4) and members of the complement system) to the bacterial cell surface is a 
major contributor to host protection. CAMPs are amphipathic molecules present on 
mammalian mucosal surfaces, in bodily secretions (such as sweat and saliva) and in 
phagocytic cells. CAMP production is a highly conserved defense mechanism of most 
organisms, but the peptides vary widely in terms of their composition and structure. The 
genes encoding CAMPs are among the most rapidly evolving mammalian genes48 and it 
has been hypothesized that this represents an example of co-evolution, wherein the genes 
are under selective pressure to mutate as a consequence of the evolution of bacterial 
resistance to them49. One of the primary mechanisms proposed for CAMP-mediated 
bactericidal activity is through association of the positively charged peptides with 
negatively charged lipid A, followed by membrane insertion and disruption of the 
membrane potential, leading to bacterial cell death43,49.  
PF4 is another positively charged host molecule that is conserved across 
vertebrates and is released upon platelet activation during infection. This molecule binds 
the bacterial cell surface at the lipid A domain. Antibodies specific for PF4-lipid A 
complexes are subsequently produced, leading to increased opsonisation and 
phagocytosis of the bacterium44. Furthermore, complement proteins also bind to lipid A 
and modulate the activation of the classical complement pathway to promote bacterial 
clearance45–47. 
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1.2.3  Lipid A is detected by Toll-like receptor 4 activation 
Lipid A is recognized by the Toll-like receptor 4-myeloid differentiation factor 2 
(TLR4-MD2) receptor, one of many pattern-recognition receptors (PRRs) of the 
mammalian innate immune system. This receptor is present on a wide variety of cell 
types including monocytes, lymphocytes and endothelial cells1. Binding of TLR4-MD2 
to lipid A triggers a signaling cascade that leads to inflammation, cytokine production 
and eventual clearance of bacteria through the recruitment of effector cells, phagocytosis, 
cytotoxicity and activation of the complement system50 (Fig. 1.3). This inflammatory 
response can be severe, resulting in tissue damage, organ failure and death, especially in 
cases of sepsis2. Unmodified E. coli lipid A, which contains six acyl chains and two 
phosphate groups, is the strongest known TLR4 ligand, and lipid A modifications can 
weaken or abolish TLR4 signaling and change the nature of the downstream cytokine 
profile (see below)51–54.   
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Figure 1.4  TLR4/MD2 signaling. 
This simplified TLR4-MD2 signalling schematic illustrates the two responses, the 
MyD88-dependent and MyD88-independent (TRIF) pathways that can be differentially 
stimulated upon binding of modified lipid A to the TLR4-MD2 complex and lead to the 
production of cytokines and ultimate pathogen clearance. MyD88-dependent pathway 
leads to the production of inflammatory cytokines, while the TRIF pathway stimulates 
the expression of interferon inducible genes that are important for adjuvanticity but are 
less inflammatory. 
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Detection of lipid A by TLR4 begins with LPS-binding protein (LBP) and cluster 
of differentiation 14 (CD-14) binding to LPS and subsequent transfer to the TLR4-MD2 
complex. This complex can then signal through two major pathways, which are named 
according to their adaptor proteins: Myeloid differentiation primary response gene 88 
(MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF)55 (Fig. 1.3). 
Severe reactions to LPS are attributed to activation of the MyD88 pathway, which 
induces the production of proinflammatory cytokines such as tumor necrosis factor α 
(TNF-α), interleukin 6 (IL-6) and interleukin 12 (IL-12). The less inflammatory TRIF (or 
MyD88-independent) pathway occurs after endocytosis of the TLR4-MD2 receptor and is 
characterized by the production of interferon-β and interferon-inducible genes such as 
interferon γ-induced protein 10 (IP-10), monocyte chemotactic protein 1 (MCP1), 
regulated and normal T cell expressed and secreted (RANTES) and granulocyte colony-
stimulating factor (G-CSF)56. Although it is important for mounting an optimal immune 
response to pathogens, the TRIF pathway does not lead to severe inflammation. 
Unmodified LPS from E. coli induces signaling through both pathways, but lipid A 
modifications can cause preferential recruitment of one adaptor protein over the other57. 
In vivo, bacterial lipid A modifications are also known to affect the potency of TLR4 
activation, as described in the following section8. 
 
1.3 BACTERIAL EVASION STRATEGIES.  
1.3.1  General evasion mechanisms 
Modification of lipid A equips Gram-negative bacteria with an ability to evade 
immune recognition and survive within a host. First, by changing the overall charge of 
the bacterial surface through the addition of chemical groups to lipid A, such as 
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phosphoethanolamine and aminoarabinose, resistance to innate immune effectors (such as 
CAMPS and complement factors) increases. Second, changes in the structure of lipid A 
are important for bacterial pathogenesis because they directly impact recognition by the 
TLR4-MD2 receptor, and both the degree of lipid A acylation and phosphorylation are 
crucial for LPS recognition by TLR4-MD251.  Bacteria can remove acyl chains and 
phosphate groups to evade detection by this PRR or to shift the type of cytokine response 
induced58. Finally, certain modifications (such as those regulated by PhoPQ) alter the 
properties of the outer membrane permeability barrier, which provides resistance to harsh 
pH and antibiotics, among other stresses.   
There are benefits and costs associated with each modification: as bacteria adapt 
to protect themselves against certain assaults, this may result in the loss of protection 
against others. For instance, PhoPQ and PmrAB-induced lipid A modifications increase 
resistance to CAMPS but constitutive activation of PmrAB has been shown to reduce E. 
coli resistance to the bile component deoxycholate59. Furthermore, PhoPQ mediated 
alterations have been shown to lower antibiotic resistance of S. Typhimurium in the 
presence of high Mg2+ concentrations25. However, these costs seem to be outweighed by a 
number of advantages of lipid A modification for bacterial virulence, which is 
exemplified by several pathogens including S. Typhimurium, Helicobacter pylori, 
Yersinia pestis and Francisella tularensis. 
1.3.2  Evasion by S. Typhimurium 
S. Typhimurium is an intracellular pathogen that causes gastroenteritis in humans. 
As a longstanding model organism for studying bacterial pathogenesis, S. Typhimurium 
provides prime examples of complex lipid A alterations (Fig. 1.1c)8. The bacterium has a 
diverse lifestyle and fine-tunes the composition of lipid A in response to the surrounding 
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environment8,60. During infection, S. Typhimurium penetrates the epithelial lining of the 
small intestine, invades lymphoid tissue and infects host phagocytes61. The unmodified 
lipid A synthesized by this organism is identical to that produced by E. coli K12 (Fig. 
1.1). However, survival is promoted in the intestinal lumen and within host cells (where 
the bacterium encounters CAMPs, low pH and possibly other unknown signals), by 
activation of the PhoPQ and PmrAB systems, leading to the addition of 
phosphoethanolamine by EptA, aminoarabinose by ArnT and acyl chain remodelling by 
PagP and PagL20 (Fig 1d). Commensal and pathogenic E. coli also encode these lipid A 
modification enzymes, but little is known about their regulation in vivo. In S. 
Typhimurium, another enzyme LpxO hydroxylates lipid A (Fig. 1.1d) as part of a 
coordinated stress response62. The combination of these modifications result in a 
remodeled outer membrane with a reduced net negative charge and increased integrity, 
which enhances virulence10,26. 
1.3.3  Evasion by Helicobacter pylori 
The human stomach is the sole niche of H. pylori, and the organism is so well 
adapted to this environment that it colonizes roughly 50% of the world’s population and 
can persist for decades63.  To survive chronically in the host and remain undetected, H. 
pylori uses two constitutive lipid A-mediated evasion strategies: repulsion of CAMPs, 
(which are present at high concentrations in the gastric mucosa) and evasion of TLR4 
detection (Fig. 1.4b). Similarly to most Gram-negative bacteria, H. pylori synthesizes a 
hexa-acylated lipid A, but displays only a tetra-acylated molecule lacking phosphate 
groups on the bacterial surface.  This striking structural difference in surface-exposed 
lipid A arises from the action of several enzymes including dephosphorylation by LpxE 
and LpxF, addition of phosphoethanolamine by EptA and deacylation by LpxR (see 
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Table 1.1). These modifications confer resistance to polymyxin B as well as other 
biologically relevant CAMPs64. Reduced acylation and phosphorylation also lead to 
decreased stimulation of TLR4 and its downstream signaling cascade51,65,66. When these 
modification systems are inactivated through mutation, H. pylori displays hexa-acylated, 
bis-phosphorylated lipid A (Fig. 1.4b), which is a strong stimulator of TLR464. The 
constitutive lipid A modifications on the acyl chains and phosphate groups are 
adaptations that allow this bacterium to persist in the harsh gastric environment amidst 
the several anti-bacterial components of the innate immune response.  
1.3.3 Evasion by Yersinia pestis and Francisella tularensis 
Y. pestis is notorious for its role in human disease throughout history, causing the 
Black Death plague that killed a third of the European population in the 14th century67. 
The bacterium has a complex life cycle, colonizing both the flea and human host68. This 
transition between hosts coincides with a switch in the composition of lipid A69 (Fig. 
1.4a).  Inside the flea, Y. pestis grows at a temperature between 21-27º C and synthesizes 
a hexa-acylated lipid A similar to the highly inflammatory E. coli lipid A that strongly 
stimulates TLR470. In humans, the bacterium encounters a temperature of 37º C and 
replaces this lipid A agonist with a tetra-acylated form that is a TLR4 antagonist. The 
tetra-acylated form of lipid A is believed to allow the pathogen to proliferate undetected 
in the bloodstream during the early stages of infection71,72. Heterologous expression of the 
E. coli acyltransferase LpxL in Y. pestis restores hexa-acylated lipid A and strong TLR4 
stimulatory properties71. Strains that are only capable of producing hexa-acylated lipid A 
are also avirulent in mice, suggesting that deacylation of lipid A is required for TLR4 
evasion and that it is crucial for Y. pestis pathogenesis71.  
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Similarly to Y. pestis, the lipid A of Fransicella tularensis is also modified 
according to temperature, affecting membrane integrity and pathogenesis in its 
environmental vectors such as protozoa and arthropods (18-26º C) and mammalian hosts 
(37º C). This organism has two homologues of LpxD, an essential lipid A biosynthetic 
acyl transferase, which incorporate longer acyl chains at high temperature (37º C) 
compared to lower temperatures (25º C and 18º C)73. A mutant strain that is unable to 
produce lipid A with longer acyl chains is avirulent in mice and is also more susceptible 
to antibiotics and CAMPs due to increased membrane permeability73. These two 
examples of lipid A modifications emphasize that appropriate adaptation in response to 
temperature is important for altering the fluidity of the outer membrane, which is needed 
to maximize virulence of Y. pestis and F. tularensis. 
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Figure 1.5  Lipid A modification strategies for survival in the host.  
H. pylori and Y. pestis evolved different mechanisms of lipid A modification to aid 
colonization of their respective host infection sites. (A) Colonizing only one ecological 
niche, H. pylori constitutively modifies all lipid A to a form that resists CAMPs and 
evades TLR4.  H. pylori lipid A is first synthesized as a hexa-acylated, bis-
phosphorylated species by the de novo pathway, but through the action of five 
modifications a tetra-acylated form lacking the 4′-phosphate group and substituted at the 
C-1 position with a phosphoethanolamine is presented on the bacterial surface. Mutating 
lpxE and lpxF inactivates this ordered modification pathway and results in a structure 
resembling E.coli lipid A.  (B) While residing in the flea-vector, Y. pestis produces an 
endotoxic, hexa-acylated lipid A.  Upon transmission to the human host, the bacterium 
senses a shift in temperature and synthesizes tetra-acylated lipid A that escapes TLR4 
detection.  
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1.4 LIPID A AS A TOOL FOR IMMUNE SYSTEM MODULATION  
1.4.1  Monophosphoryl lipid A 
Through chemical or biological modification to its phosphate groups and acyl 
chains, the therapeutic potential of lipid A can be harnessed while limiting the 
inflammatory effects of the molecule51,55,65. In fact, a chemically detoxified mixture of 
mono-phosphorylated lipid A species (MPL), derived from Salmonella minnesota (see 
figure for the structure of the predominant species, 3-O-deacyl-4ʹ′-monophosphoryl lipid 
A), recently became the first FDA-approved vaccine adjuvant in over 70 years, bringing 
the number of FDA-approved TLR agonists up to three55,74. We predict that TLR ligands 
are likely to be the future of vaccines and could benefit other areas as well, such as cancer 
research, gene therapy and bacterial production of pharmaceuticals. 
Lipid A derivatives like MPL have been well-studied for their agonistic properties 
in terms of immune stimulation55. However, MPL is the only lipid A that has been tested 
in human cancer vaccine trials75, and almost all studies have focused on cervical cancer, 
since MPL is used as the vaccine adjuvant against the oncogenic human papilloma virus 
(HPV)74. Considering the evidence that TLR4 signalling can be biased to produce certain 
types of cytokine responses57, further study of other modified lipid A structures as well as 
chemically synthesized lipid A variants76 could prove advantageous for development of 
vaccine adjuvants. To facilitate such work, we have engineered an E. coli library to 
synthesize lipid A variants with a spectrum of endotoxicity77. These lipid A variants have 
the potential to be used as components of whole cells, LPS or purified lipid A and might 
be used as vaccine adjuvants in the future.  
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Figure 1.6  Monophosphoryl lipid A forms 
(A) 4’-monophosphoryl lipid A as produced in E. coli expressing a 1-phophatase. (B) 
The structure of the predominant species in the 3-O-deacyl-4ʹ′-monophosphoryl lipid A 
(MPL) mixture that is chemically detoxified from S. minnesota and used as a vaccine 
adjuvant due to its bias toward the TRIF rather than MyD88-dependent TLR4-MD2 
signalling pathways. 
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Whole cell vaccine strains of some organisms, such as Salmonella Typhimurium, 
have been engineered to synthesize altered lipid A structures to reduce their toxicity. 
Heterologous expression of an antigen from Streptococcus pneumoniae in such strains, 
provides protection against both S. Typhimurium and S. pneumoniae52,53. Similarly, outer 
membrane vesicles from Neisseria meningitidis with modified lipid A are now prime 
candidates for vaccination against Neisseria meningitidis78 and other organisms, in which 
antigens can be heterologously expressed and targeted to the vesicle lumen or surface79.  
1.4.2  Further potential of lipid A in therapeutics 
The high inflammatory response to E. coli is also an obstacle to gene therapy. 
Gene therapy strains are engineered to lyse upon phagocytosis and transfer a plasmid 
with mammalian expression machinery to the host80. For this purpose, a strain producing 
penta-acylated lipid A was generated to reduce the proinflammatory activity81, but an 
intermediate immune response might offer an elegant balance between high phagocytosis 
and lowered endotoxicity. Gene therapy strains can also be engineered to colonize tumors 
and express tumor antigens to initiate an oncolytic response.  This reaction is partly due 
to the lipid A/TLR4 response and the production of tumor necrosis factor75.  In fact, lipid 
A immunogenicity has long been shown to be responsible for tumor regression in various 
models and tissue types82.   
One major hindrance to the use of purified LPS and lipid A as cancer drugs is 
tolerance.  Tolerance develops even after one treatment, with downregulation of the 
immune response to LPS. Although this is detrimental to cancer treatment, it is a 
beneficial development for protection against sepsis for immunosuppressed patients83. 
Some lipid A analogs, such as MPL, induce less tolerance than LPS75,84. Direct 
comparison between lipid A structures could provide insight into the mechanism of 
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tolerance, potentially decrease tolerance for tumor regression treatments, or increase it for 
protection against endotoxic shock.   
Tolerance has excluded MPL from cancer treatments but has not eliminated it 
from attention as a cancer vaccine adjuvant.  In fact, although many synthetic analogs are 
being investigated, MPL is the only lipid A to date that has been tested in human clinical 
cancer vaccine trials75. Considering the evidence that TLR4 signaling can be biased to 
produce certain types of responses, other lipid A structures should be explored as well.  
Few studies have directly compared the effects of other lipid A structures to MPL and to 
LPS55.  However, lipid A is insoluble and requires adsorption onto other adjuvants to 
enable delivery55, so a modified LPS could offer more options for a soluble molecule with 
the lowered endotoxicity of MPL.  Our combinatorial approach applied herein allows 
investigation into the potential for custom induction of immune responses.  
The engineering of modified LPS molecules could also greatly impact subunit 
vaccine development.  In cancer vaccines and other subunit vaccines, pathogen specific 
antigens are often too weakly immunogenic to be effective55.  Thus, insufficient 
immunogenicity can be enhanced by lipid A or LPS adjuvants, and those antigens with 
intermediate immune responses can be slightly elevated by selecting LPS molecules from 
the library. Certain antagonistic species could also be valuable as antisepsis drugs to 
reduce the high number of deaths in intensive care units due to septic shock85.  
Additionally, supplementation with antagonist species of LPS has been shown to 
downregulate a hyperinflammatory response to some antigens or whole cell vaccines86. 
E. coli is ideal for inexpensive mass production of molecules such as DNA and 
protein, but LPS is a major contaminant in such pharmaceutical preparations.  To purify 
samples within the safe clinical grade limits, many purification methods have been 
developed87–89.  Unfortunately, the variety of biotechnological applications utilizing E. 
 27 
coli makes it difficult to establish general methodologies for removal of LPS90. 
Additionally, these steps often sacrifice yield for purity, add hours to sample preparation, 
and require large-scale, expensive disposable supplies91.  Using E. coli strains with a 
decreased threat of endotoxic impurity will eliminate the need for difficult purification 
methods. 
To satisfy both pharmaceutical and therapeutic needs, lipid A would ideally be 
available in a spectrum of endotoxicity. Minimal endotoxicity is desirable for bacterial 
expression systems, whereas modest immunogenicity is more suitable for safe use in 
vaccines.  For such diverse needs, a synthetic lipid biology approach was followed for 
this work in order to provide a set of E. coli strains that could be utilized as cells, LPS, or 
lipid A suitable for numerous applications.   
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Chapter 2: Modulating the immune response by combinatorial 
engineering of endotoxin2 
 
2.1 INTRODUCTION 
In 1892, Richard Pfeiffer introduced the revolutionary concept of bacterial 
endotoxin in his description of a non-proteinaceous, non-secreted toxin bound to the 
surface of Vibrio cholerae92.  This toxin, lipopolysaccharide (LPS), is the major surface 
molecule of Gram-negative bacteria that triggers the host immune response during 
infection through recognition of the bioactive lipid A domain2.  Lipid A, or endotoxin, is 
recognized by the innate immune system through the conserved pattern recognition 
receptor, Toll-like receptor 4/myeloid differentiation factor 2 (TLR4/MD-2) complex, 
which initiates a robust signal cascade leading to cytokine production that is crucial for 
clearance of infection but can be potent enough to result in lethal endotoxic shock1.  
The structural nature of Escherichia coli lipid A, with six acyl chains and two 
phosphate groups, is critical for complete activation of human TLR4/MD-251.  Many 
bacteria have evolved enzymes that alter their lipid A structure by modifying its number 
of acyl chains, phosphate groups, or polar functional groups93.  Such modifications can 
alter the strength of the TLR4 response.  For instance, hexa-acylated lipid A is maximally 
stimulatory, while tetra-acylated lipid A is antagonistic51. Lipid A modifications can also 
lead to stimulation of select TLR4 signaling pathways by mediating the recruitment of 
distinct sets of adaptor proteins: MyD88 (myeloid differentiation primary response gene 
88), TRIF (TIR-domain-containing adaptor-inducing interferon-β), or both55.  While 
                                                
2 Large portions of this chapter have been previously published. Needham, B. D. et al. 
Modulating the innate immune response by combinatorial engineering of endotoxin. 
Proc. Natl. Acad. Sci. U. S. A. 110, 1464–1469 (2013) 
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strong induction of the MyD88 pathway is harmful due to high production of 
proinflammatory cytokines including TNF-α and IL-1β, a low level of induction is 
beneficial for long-lasting immunity in vaccines55.  TRIF-mediated responses produce 
lower quantities of inflammatory cytokines, yet are still effective in triggering production 
of cytokines important for vaccine adjuvants such as IRF-3 inducible genes56.   
Efforts to understand the lipid A-TLR4 interaction have yielded improved 
vaccines78.  Notably, one LPS derivative with reduced toxicity, termed MPL, has been 
approved to supplement an adjuvant system in vaccines worldwide55.  MPL is a 
heterogeneous mixture of lipid A species from Salmonella minnesota R595 that has been 
chemically detoxified by successive acid and base hydrolysis94.  The primary lipid A 
species of the MPL mixture is 3-O-deacyl-4ʹ′-monophosphoryl lipid A (Fig. 1.5), which 
induces a stronger TH1 response than classical adjuvants such as aluminum salt 
precipitates (alum)55 but unlike LPS, induces a signaling bias toward the TRIF pathway, 
resulting in the safe stimulation of adaptive immune responses without excessive 
production of inflammatory cytokines57.  Efforts to engineer E. coli strains for simplified, 
biological production of MPL have not been successful thus far.  E. coli strains that are 
dephosphorylated at the 1-position have been developed95; however, the acyl chain 
arrangement in lipid A from these strains varies structurally from the predominant 
Salmonella 3-O-deacyl-4ʹ′-monophosphoryl lipid A in MPL94.   
Immunomodulation by LPS variants has been recognized as a potentially 
advantageous therapeutic strategy for many circumstances78,80,95. Additionally, the lipid A 
modifying enzymes utilized in the present study have been individually expressed in wild 
type E. coli and/or Salmonella for proof of function96–101, and two strains have been 
generated in which two coexpressed enzymes (LpxE/LpxF, and PagP/PagL, respectively) 
resulted in lowered antagonistic properties102,103. However, lipid A heterogeneity, its 
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essentiality to bacterial growth, the complexity of lipid A biosynthesis, and the analytical 
challenges posed by lipidomics have previously impeded the engineering of a single 
species of bacteria capable of producing nearly any lipid A species.  Here, we report a 
system for the combinatorial engineering of E. coli strains that produce lipid A variants 
with distinct TLR4 agonist functions and a broad range of effect on the mammalian 
immune response (Fig. 2.1). Our method shows that coexpression of individual enzymes 
is not effective compared to combinatorial expression.  Additionally, in many instances 
the engineered strains produce highly homogeneous lipid A, a feature that is particularly 
attractive for therapeutics development.  These strains have provided a means to directly 
compare whole cells, intact LPS, and lipid A in the same background, eliminating 
confounding factors present when using different bacteria to compare lipid A structures 
(some not naturally found in nature).  Chemical synthesis of many of these lipid A 
structures is complicated due to varied length of primary acyl chains and asymmetric acyl 
chain arrangement104.  Also, chemical synthesis cannot be used in settings where whole 
bacterial cells or purified, intact LPS is required.  We report on the construction and 
characterization of a library of 61 distinctive, engineered strains that mediate graded 
TLR4 dependent cytokine responses in vitro, and result in robust IgG titers following 
immunization of mice with antigen/lipid A-variant emulsions.    
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Figure 2.1  Combinatorial engineering of lipid A to generate diverse immune responses.  
A schematic is shown illustrating how the outer surface of E. coli strains varies in LPS 
structure (indicated by different colors) when plasmids are expressed that contain 
combinations of up to five lipid A modifying enzymes. The altered LPS molecules bind 
and activate the TLR4/MD-2 complex differentially, altering the nature of downstream 
cytokine production, represented by shapes that indicate different types and quantity of 
cytokines released. 
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2.2 RESULTS 
2.2.1  Combinatorial engineering of lipid A. 
 First, to generate an E. coli library with defined lipid A domains of LPS, we 
generated two background strains that synthesize homogeneous lipid A by deletion of the 
genes that modify E. coli lipid A under normal growth conditions (see Experimental 
Procedures, Table 5.1).  Specifically, strain BN1 was generated from strain BN0, an lpxT 
and eptA double mutant. The LpxT enzyme functions to add a third phosphate group to 
lipid A, and when mutated the resulting lipid A is strictly bis-phosphorylated105.  
However, LpxT inhibition activates EptA, which adds a phosphoethanolamine to the 1-
position of lipid A35.  Mutation of lpxT and eptA increases the activity of PagP to 
palmitoylate the 2-acyl chain of lipid A35, so the pagP gene was also deleted. As a result, 
strain BN1 produces hexa-acylated, bis-phosphorylated lipid A, the highly endotoxic, 
major species synthesized by E. coli8.  Deletion of lpxM in BN1 generated strain BN2, 
which synthesizes only penta-acylated lipid A.   
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Figure 2.2  Confirmation of mutant BN1 and BN2 strains.  
Radiolabeled lipid A of W3110 (E. coli K12), BN1, MLK1067, and BN2 was separated 
by TLC (a).  W3110 synthesizes hexa-acylated lipid A with either two or three phosphate 
groups.  BN1 is an eptA, lpxT, pagP mutant that loses the capacity to synthesize the lipid 
A species with three phosphate groups.  These genes were deleted to eliminate 
modifications to the lipid A that occur under normal growth  conditions22.   MLK1067 is 
an lpxM mutant of W3110 that synthesizes penta-acylated lipid A.  BN2 is an lpxM 
mutant of the BN1 strain that produces only penta-acylated, bis-phosphorylated lipid A. 
b,c) BN1 and BN2 lipid A was analyzed by MALDI-TOF MS in negative ion linear 
mode.  Ion peaks correspond to an appropriate exact mass (±1) for BN1 hexa-acylated 
lipid A with two phosphates at m/z 1797.2 and BN2 penta-acylated lipid A with two 
phosphates at m/z 1587.0. 
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Thin-layer chromatography (TLC) and MALDI-TOF mass spectrometry (MS) 
confirmed the lipid A profiles (Fig. 2.2).  BN1 and BN2 provide two distinct templates 
suitable for alteration by endotoxin modifying enzymes, and expression of any individual 
or combination of lipid A modification enzymes in these strains generates strains, 
distinctive in their homogeneous lipid A background.  Additionally, 36 of these include 
combinations of enzymes that have not previously been co-expressed in any strain, which 
provides 61 new strains when introduced into the two backgrounds.   
BN1 and BN2 were transformed with a single vector, which allows the expression 
of an unrestricted number of proteins106, harboring combinations of genes encoding lipid 
A modification enzymes from different bacterial species, specifically PagP from E. coli, 
PagL, LpxR, and LpxO from Salmonella enterica serovar Typhimurium, and LpxE and 
LpxF from Francisella tularensis (Fig. 2.2b, Table 5.1)8.  Since LpxF from F. tularensis 
is known to not function on hexa-acylated lipid A substrate8,99, LpxF was not introduced 
into BN1. Additionally, LpxO from S. enterica hydroxylates the 3ʹ′-acyloxyacyl chain101 
that is absent in BN2, precluding its use in this strain background.  
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Figure 2.3 Modification machinery used to generate diversified lipid A molecules in 
whole bacteria. 
Lipid A structures of wild-type E. coli K12, BN1, and BN2 are shown with the names of 
the 6 lipid A modifying enzymes represented in color next to the group that each enzyme 
modifies: LpxR (green), PagL (blue), LpxE  (brown), LpxF (purple) all remove the 
corresponding group.  LpxO (orange) and PagP  (red) transfer the group onto the 
molecule.  The attachment site for remaining polysaccharide is indicated at the 6ʹ′-
position of each molecule (a).  The organism source, activity, and active site topology of 
each of the 6 enzymes (b), and the 61 combinatorial strains (c) are presented.  
Combinatorial strains were generated by transformation of BN1 and BN2 with a 
pQLinkN plasmid expressing combinations of the 6 lipid A modifying enzymes.  Each 
enzyme is abbreviated by its final letter and ordered alphabetically in the plasmid name, 
i.e., LpxE is abbreviated E, LpxF is F, LpxR is R, PagP is P, PagL is L, and LpxO is O.   
 
 
  
 
 36 
To confirm activity of the lipid modifying enzymes, 32P-labeled lipid A isolated 
from the 61 engineered E. coli strains was analyzed by TLC, revealing 61 distinct lipid 
profiles, as expected.  Fig. 2.3a demonstrates the variety of endotoxin species produced in 
BN1 and BN2 expressing combinations of lipid A modifying enzymes (Fig. 2.3a).  11 
strains synthesized nearly homogeneous lipid A (Appendix), such as BN2 expressing 
PagL (strain BN2 pL) that produces 99.2% tetra-acylated lipid A (Fig. 2.3a).  This is rare 
in nature, as a heterogenous mixture of lipid A species is found on the surface of most 
Gram-negative bacteria8.  An additional 8 strains produce at least 75% homogeneous 
lipid A (Appendix), while other strains (e.g. BN2 pELPR) produce a more heterogeneous 
mixture as a consequence of the substrate specificity and limited expression level of the 
transmembrane lipid A modifying enzymes (Fig. 3a).  While this heterogeneity was not 
our initial goal, the fact that the FDA approved adjuvant MPL is a mixture, as well as the 
fact that all current whole cell vaccines synthesize heterogeneous lipid A, indicated that a 
reproducible mixture could be just as valuable as a single uniform lipid A species.  Each 
strain was grown and analyzed at least three times to confirm reproducibility in the lipid 
A profile for these mixtures.  
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Figure 2.4  Analysis of engineered lipid A molecules. 
TLC of 32P labeled isolated lipid A from combinatorial strains is shown to illustrate the 
diversity within the collection (a). This method allows species separation, identification, 
and quantification based upon hydrophobicity-mediated migration.  Mass spectrometry of 
isolated lipid A from selected strains allows further identification of lipid A species (b-d).  
BN1 pE produces a major peak at m/z 1716.8, consistent with the expected removal of 
one phosphate group (b).  BN2 pLR produces a major peak at m/z 1133.9, corresponding 
to the mass of a tri-acylated lipid A molecule (c).  This is contrasted with BN1 pELR (d), 
which produces a predominant peak at m/z 1053.6, corresponding to the 
dephosphorylation of the major peak seen in BN1 pLR.  Minor peaks in both of these 
strains are similar.  Peaks at m/z ~1360 and ~1570 correspond to masses of lipid A 
resulting from a single deacylation by either LpxR or PagL, respectively.  The peak at 
m/z ~1796 corresponds to residual unmodified BN1 lipid A.  In BN1 pLR, there is a 
slight loss of the labile 1-phosphate group from the major species, yielding a peak at m/z 
1054.0.  
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In addition to TLC analysis, all lipid A species in the library were analyzed by 
MS, which allowed structural characterization based on mass and expected enzyme 
activities (Appendix).  Figure 2.4 highlights examples of MS results for three categories 
of lipid A modifications: phosphate modified (b), acyl chain modified (c), or a 
combination of both (d).  The mass spectrum of BN1 pE revealed a major peak at m/z 
1716.8 corresponding to the removal of one phosphate group.  Strain BN1 pLR yielded a 
major peak at m/z 1133.9 corresponding to a tri-acylated lipid A, resulting from 
deacylation by PagL and LpxR.  Cells expressing LpxE, PagL, and LpxR (BN1 pELR) 
yield lipid A producing a major peak at m/z 1053.6 corresponding to tri-acylated mono-
phosphorylated lipid A.  These results indicate that through logarithmic growth, E. coli 
can tolerate drastic changes to its normally tightly regulated lipid A profile (Fig. 2.5). 
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Figure 2.5  Growth curve of engineered strains. 
An example graph is shown that represents the growth curve of the strains.  All 61 strains 
reach an OD600 of at least 0.8, although some do not survive stationary phase in 96-well 
plate format, as represented by strain BN1 pR in purple.  The background strain, BN1 is 
shown in black.  The blue square indicates the target cell density when cells were 
harvested for experiments. 
  
 
  
 
 40 
Coexpression of these enzymes allowed further characterization of the substrate 
specificity of the enzymes themselves.  For example, the crystal structure of LpxR and 
modeling of the structure with lipid A, did not indicate any important interactions of the 
enzyme with the 1-phosphate group of lipid A107.  The enzyme is Ca2+ dependent, and the 
4'-phosphate group interacts with this cation.  However, analysis of our strains that 
express LpxR in combination with the phosphatases LpxE and/or LpxF has shown that in 
the BN1 hexa-acylated background, the deacylase has increased activity (almost 100%) 
in the presence of LpxE, which removes the 1-phosphate group in the inner membrane 
before the lipid A molecule reaches LpxR in the outer membrane during synthesis and 
transport.  In the penta-acylated BN2 background, removal of the 4'-phosphate group by 
LpxF completely abolishes LpxR activity, but LpxE activity does not.  This is interesting 
since in Francisella LpxF mutants the 3'-acyl chain is retained, indicating the LpxF 
activity actually enhances LpxR activity in this organism99. 
2.2.2  Differential TLR4 stimulation by whole bacteria and LPS with modified lipid 
A. 
To examine the range of TLR4 activation induced by whole bacterial cells 
producing diverse lipid A structures, we screened our library using HEK-Blue™ hTLR4 
cells.  These cells express TLR4, MD2, CD14 and the NF-kB and AP-1-dependent 
reporter, secreted embryonic alkaline phosphatase (SEAP).  The reporter cell line was 
challenged with a range of colony forming units (CFU) of each of the 61 lipid A library 
strains.  At 104 CFU/well, 51 of the strains displayed significantly different TLR4 
responses relative to the BN1 control strain that produces wild-type lipid A (p<0.05).  
Additional controls used were the bis-phosphorylated, hexa-acylated W3110 parent strain 
and the bis-phosphorylated, tetra-acylated strain CMR300, which acts as a TLR4 
antagonist.  For direct comparison between strains, the data is presented colorimetrically  
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Figure 2.6  TLR4 stimulation by whole cells and purified LPS. 
Stimulation of TLR4 following incubation of whole bacterial cells with HEK-Blue cells 
expressing TLR4, MD2, and CD14 is depicted (a).  The TLR4 responses to whole cells 
are shown for all strains. Colors were assigned based on the TLR4 stimulation results in 
the BN1 strain. Rational for colorimetric designations is displayed in Fig. S3.  The 
positive control is E. coli K12 strain W3110, the parent strain of the mutants used in this 
study.  The negative control for this assay is strain CMR300, an E. coli strain that 
produces only lipid IVA, a tetra-acylated TLR4 antagonist. The * indicates p<0.05 at 104 
CFU/well.  HEK-Blue-TLR4-MD2-CD14 cells were also incubated with increasing 
concentrations of LPS from 13 of the 61 engineered strains (b).  E. coli K-12 LPS was 
used as a positive control and R. sphaeroides LPS, a known TLR4 antagonist, served as a 
negative control.  The * and ° indicate p<0.05 at 1.0 and 10 ng/ml, respectively. 
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Figure 2.7  Colorimetric designations based on TLR4 stimulations by BN1. 
Selected samples are shown in the graph to illustrate the range of TLR4 stimulation that 
results from incubation of whole bacteria cells with HEK-Blue cells expressing TLR4, 
MD-2 and CD14.  Color scale of is based on the stimulation curve of the BN1 sample and 
represents the delineations of the colorimetric scale used in Fig. 2.6. 
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(Fig. 2.6a, Fig. 2.7), and all graphical data is supplied in Appendix X.  Similar TLR4 
assays were also performed using 0.1-100 ng/mL of isolated LPS from 13 of the strains 
(Fig. 2.6b, Appendix B).  In all experiments, LPS and lipid A samples are quantified and 
normalized according to number of molecules.  All LPS samples except BN1 pE induced 
significantly lower TLR4 activation than BN1 LPS at 1 ng/ml (p<0.05), and a similar 
trend was observed between cells and purified LPS (Fig. 2.6).  To show full induction, 
pure hexa-acylated LPS was used, and R. sphaeroides LPS, a known TLR4 antagonist, 
was used as a negative control.  While the effects of some lipid A modifications on LPS 
immunogenicity have been reported52,103, our combinatorial approach generated a 
surprisingly diverse range in agonistic TLR4 stimulation and illustrated the need for 
further characterization of the TLR4-lipid A interaction due to the unpredictable results 
for many of the strains.  This technique also allows investigation into reproducible 
mixtures of agonistic and antagonistic lipid A species within a bacterial cell that could 
prove optimal for adjuvant activity due to a reduction in TLR4 activation compared to 
wild type cells and LPS. 
In this TLR4-specific assay, stimulation by BN1 bacterial cells expressing a 
single lipid A modifying enzyme generally did not differ from the BN1 parental strain, 
even in BN1 pL, in which PagL cleaves the majority of the lipid A at the 3-position to 
yield a penta-acylated form predicted to be less inflammatory65 (Fig. 2.6, Appendix A).  
This was surprising, considering the reports from others that purified lipid A modified 
individually by PagL, PagP, or LpxE shows a reduction of TLR4 antagonism55,108.  The 
limited alteration of the TLR4 response to whole bacterial cells expressing only one lipid 
A modifying enzyme validates the combinatorial approach using multiple enzymes to 
generate molecules with varied TLR4 activity.  For example, in strain BN1 pLPR, single 
expression of PagL or PagP, or LpxR results in very high or very low TLR4 stimulation, 
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respectively.  However, when all three enzymes are co-expressed, an intermediate 
activity is displayed (Fig. 2.6a). 
We found that the TLR4 response of strains ranging from completely inactive to 
slightly active could be enhanced when expressed in combination.  For example, in the 
penta-acylated BN2 background strain, expression of PagP with either or both 
phosphatases, LpxE and LpxF, (strains BN2 pFP, BN2 pEP, and BN2 pEFP) stimulate 
TLR4 almost at wild type levels at high cell counts, yet BN2 alone and each of the 
enzymes expressed individually in BN2 (BN2 pP, BN2 pE, and BN2 pF) are all much 
less stimulatory and some of them might even act antagonistically.  Removal of either 
phosphate group from lipid A was expected to decrease the interaction with TLR451, but 
instead we see that in combination with PagP, the phosphatases act to make the strains 
more endotoxic.  We observe a similar phenomenon in other strains, for example BN2 
pLP and BN2 pFL, which each induce a higher TLR4 response than any potential 
subspecies within the strain (Fig. 2.6a).  These results clearly demonstrate that TLR4 
stimulation is substantially affected by the combinatorial expression of lipid A modifying 
enzymes in a manner that does not necessarily reflect the expected results from individual 
expression of each enzyme. 
The importance of acyl chain position on the lipid A molecule during TLR4 
activation has been difficult to study in the past because comparing different bacteria that 
synthesize lipid A with varied acyl chain position is not a controlled system.  Our strains 
enable a direct comparison.  As an example, BN2 is penta-acylated and does not 
stimulate TLR4 at any of the tested cell concentrations.  As expected, expression of PagP 
(strain BN2 pP) increases activity, since it converts some of the lipid A to hexa-acylated, 
but not nearly as much as the highly endotoxic, wild type hexa-acylated E. coli lipid A.  
However, it is surprising that when PagL (strain BN1 pLP) is expressed, (another acyl 
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chain is removed and the strain then synthesizes more penta-acylated lipid A) instead of 
decreasing, the TLR4 stimulation increases (Fig. 2.8).   
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Figure 2.8  An example of the effect of acyl chain position on TLR4 activation. 
BN2, which is penta-acylated, is unstimulatory.  Expression of PagP in the BN2 strain 
increases stimulation.  Including PagL expression, in BN2 pLP, further increases 
stimulation, even though more lipid A molecules are then penta-acylated.    
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2.2.1  Lipid A modification is sufficient to reduce stimulation of monocytes 
expressing multiple pattern recognition receptors. 
Next, we investigated whether alteration of the TLR4 response through the lipid 
A modifications in the library are sufficient to alter the overall innate immune response, 
even in THP-1 (human acute monocytic leukemia) cells that also recognize many 
conserved bacterial patterns such as flagellar proteins, lipoproteins, and peptidoglycan in 
addition to LPS.  To do so, bacterial cells were used to stimulate THP1-XBlueTM-MD2-
CD14 cells expressing all TLRs, NOD1 and NOD2 (nucleotide-oligomerization domains 
responsible for peptidoglycan recognition) proteins along with the SEAP reporter system 
that responds to stimulation of any TLR or NOD pathway.  Engineered E. coli strains that 
resulted in reduced TLR4-specific activation in HEK-Blue hTLR4 cells (Fig. 2.6) also 
resulted in a reduced overall THP1-XBlueTM-MD2-CD14 response (Fig. 2.9a), revealing 
that the innate immune recognition of 103-105 CFU/well of engineered E. coli is 
dominated by TLR4 activation by the lipid A moiety of LPS and not by signaling through 
other Toll-like receptors.  
2.2.1  Cytokine profile of human monocytes stimulated by LPS. 
To evaluate the cytokine profile elicited by LPS containing various lipid A 
modifications, we determined the concentrations of the MyD88-dependent cytokines, 
TNF-α, IL-6, IL-1β, and IL-8, and the TRIF-dependent cytokines, G-CSF, RANTES 
(CCL5), and MCP-1 (CCL2), after 24 hr incubation with 100 ng/ml LPS (Fig. 2.9b,c).  A 
full spectrum of cytokine levels was observed, ranging from strong stimulation by LPS 
from the BN1 parental strain to minimal stimulation elicited by BN2 LPS.  Interestingly, 
LPS from some strains retained the capacity to preferentially stimulate certain cytokines.  
For example, BN1 pLPR maintains 40% of the MCP-1 level compared to BN1, yet G-
CSF production is almost completely abolished (Fig. 2.9c).  Another instance of variable 
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production of cytokines was observed in IL-8 levels, as shown by BN2 pEP that 
stimulates IL-8 production equal to BN1, while all other cytokine levels were greatly 
diminished (Fig. 2.9b).  As MCP-1 and IL-8 are important for T-cell protective immune 
responses, retention of their stimulation could be valuable to immune modulation, 
especially with the combined reduction of other inflammatory cytokines109,110. These 
results highlight how chemical modifications in LPS can impart a broad range of agonist 
properties to modulate cytokine production. 
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Figure 2.9  Engineered strains induce diverse stimulation and cytokine production in vitro 
and high IgG titers in vivo.  
THP1-XBlue monocytes expressing all TLRs, Nod1, Nod2, MD-2, and CD14 were 
incubated with whole bacterial cells, and overall innate immune receptor activation was 
measured. The graph of representative samples illustrates that in the range of 103-105 
CFU/well the activation of the THP1 cells was reduced, and all samples were 
significantly different from BN1 at 104 CFU/well (p<0.001).  (b) Production of TRIF 
pathway cytokines (G-CSF, RANTES, and MCP-1) and MyD88 pathway cytokines 
(TNF-α, IL-6, IL-1β, and IL-8) by wild-type THP-1 monocytes differentiated into 
macrophage-like cells when incubated with 100 ng/ml LPS (b, c).  Cytokine levels are 
presented as percent of the BN1 level.  (d) BALB/cJ mice were immunized with 50 µl of 
an emulsion of 30 µg lysozyme from chicken egg white (HEL) with 6 pM of purified 
lipid A and serum was analyzed by ELISA.  All lipid A adjuvants tested (BN1 pELP, 
BN1 pPR, BN2 pEP, and BN1 pLPR) induced a high IgG response, and only BN2 pEP 
was significantly lower than the MPL control (p=0.0009). 
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Figure 2.10  Cytokine analysis of serum from immunized mice. 
Immunized mice were bled 24 hours after final immunization and cytokine levels in 
serum were measured by Luminex.  
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2.2.1  Engineered lipid A samples induce a stronge acquired immune response in 
mice. 
To investigate the adjuvant potential of strains in this library, BALB/cJ mice were 
immunized with emulsions of hen egg white lysozyme (HEL) and purified lipid A from 4 
strains, BN1 expressing LpxE, PagL, PagP (BN1 pELP), BN1 expressing PagP and LpxR 
(BN1 pPR), BN2 expressing LpxE and PagP (BN1 pEP), and BN1 expressing PagL, 
PagP, and LpxR (BN1 pLPR).  In this experiment we used purified lipid A for direct 
comparison to MPL, which consists of only the lipid A domain of LPS.  All tested lipid 
formulations resulted in high anti-HEL IgG titers, and only the BN2 pEP titer was 
statistically significantly lower than MPL (Fig. 2.9d).  Cytokine analysis of the serum 
revealed a low inflammatory response measured by equivalent TNF-α levels between 
adjuvants, and modest variation in some cytokines such as G-CSF (Fig. 2.10).  These 
responses in mice indicate that the combinatorial strains could facilitate biological 
production of safe adjuvants that are as effective as those currently used, such as MPL.  
Although animal models are quite useful in testing potential adjuvants, human and 
murine TLR4-MD2 display differential recognition of LPS.  For example, tetra-acylated 
lipid A is an antagonist of human TLR4-MD2, but an agonist of murine TLR4-MD2111.  
This could explain the surprisingly uniform response in mice observed between lipid A 
samples, which can be partially attributed to lower specificity in ligand binding in the 
murine TLR4 compared to human TLR4, such that a wider diversity in human response 
to lipid A adjuvants from the library might be expected54. Unfortunately, a humanized 
mouse was not yet available during this work to compare the murine cytokine response to 
the adjuvant directly with human TLR4 response. 
The high IgG response to lipid A from strain BN1 pELP is noteworthy because 
this strain produces lipid A species characteristic of the MPL mixture derived from S. 
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minnesota LPS (Appendix A, Fig. 2.11).  Nonetheless, lipid A from BN1 pELP and the 
similar strain BN1 pELOP produce a higher percentage of the predominant species, 3-O-
deacyl-4ʹ′-monophosphoryl lipid A found in commercial MPL preparation from S. 
minnesota (Fig. 2.11).  This finding indicates that engineered E. coli can potentially be 
employed to produce high purity MPL, thus eliminating the need for extensive chemical 
treatment of S. minnesota LPS required to generate the adjuvant94.  To ensure that 
purification of the 3-O-deacyl-4ʹ′-monophosphoryl lipid A species is feasible, we 
performed liquid chromatography and analyzed the purified species by MS, confirming 
the isolation of the species of interest (Fig. 2.11).  
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Figure 2.11  Mass spectra of engineered strains compared to MPL from S. minnesota.  
MS data is presented of MPL from S. minnesota, the two strains from the library that 
produce similar profiles, even without additional chemical treatment, and the purified 3-
O-deacyl-4ʹ′-monophosphoryl lipid A.  Colored boxes indicate structures with the same 
phosphorylation and acyl chain patterns.  Red box indicates the hydroxylated and 
nonhydroxylated 3-O-deacyl-4ʹ′-monophosphoryl lipid A, the most notable species of 
MPL. 
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2.2.1  Discussion 
We report that combinatorial expression of lipid A modifying enzymes in E. coli 
results in an array of strains with structurally diverse lipid A species that induce 
differential TLR responses and cytokine profiles, many of which could not be predicted 
based on previous data of the TLR4-lipid A interaction. Modified LPS from these 
engineered strains can be utilized as (i) the major immunogenic surface component of 
whole bacteria, (ii) a purified LPS molecule, or (iii) free lipid A molecules following LPS 
hydrolysis.  The effect of some lipid A modifying enzymes on TLR4 agonist activity 
were previously unreported.  For example, we show that LpxR activity diminishes TLR4 
stimulation, as expected due to reported effects of reduced acylation65.  The results of 
some strains could not have been predicted based on previous work on the importance of 
acylation and phosphorylation of lipid A51, e.g. BN2 pFL, which generates tetra-acylated 
and 4ʹ′-dephosphorylated lipid A yet consistently shows higher TLR4 stimulation than its 
penta-acylated, bis-phosphorylated parent (Fig. 2.6a).  Other strains, such as the 
extensively modified monophosphorylated, tri-acylated lipid A of strain BN1 pELR, 
show that E. coli tolerates severe alterations in lipid A structure through removal of three 
of its six lipid A acyl chains and one phosphate group without apparent growth defects 
(Fig. 2.4a,c). This library provides a versatile tool and illustrates the utility of E. coli for 
production of modified lipid A molecules.  
The diversification of modified LPS molecules that induce distinct cytokine 
responses offers the potential to produce new adjuvants that may be able to modulate 
humoral immune responses for more effective and longer-lasting protection.  Although 
intact LPS or lipid A molecules from the library could allow pairing of adjuvants suitable 
for the desired response of a particular antigen, lipid A is insoluble and requires 
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adsorption onto alum to enable delivery55.  Thus, detoxified whole LPS may be a more 
attractive soluble adjuvant.  
This combinatorial library also provides tools to overcome hurdles in other 
aspects of industry, such as DNA and protein expression, gene therapy, and drugs for 
anti-sepsis or cancer.  E. coli is ideal as an inexpensive, high-level expression strain, but 
LPS is a major contaminant in such preparations.  Using E. coli strains with a diminished 
threat of endotoxic impurity could improve the safety of these preparations.  Altered 
immunogenicity of whole E. coli cells through combinatorial diversification of lipid A 
would also improve gene therapy strains.  Bacteria can be engineered to present antigen 
in tumors or invade particular tissues to transfer genetic material to a host, and a strain 
that selectively modulates the immune response could provide an optimal vector for such 
mechanisms80,95.  In addition to lowered toxicity important for expression and gene 
therapy strains, some lipid A species from the library could possess antagonistic 
properties that inhibit TLR4 signaling.  As antisepsis drugs, they could serve to block the 
strong inflammatory response during to septic shock85.  In this work, we have followed a 
synthetic lipid biology approach to generate a combinatorial library of lipid A molecules 
to satisfy a wide array of biotechnological and therapeutic needs, the scope of which will 
continue to broaden as further investigation into the potential of these strains is 
completed.  
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Chapter 3: Determining the effects of altering the secondary acyl chain 
length of E. coli lipid A 
 
3.1 INTRODUCTION 
Gram-negative bacteria are equipped with mechanisms to modify their protective 
outer membrane in order to adapt to hostile and dynamic environments12. Yet certain 
aspects of the outer membrane barrier remain strictly uniform34. The major exterior 
molecule of the outer membrane, lipopolysaccharide (LPS), displays both of these 
characteristics; the well-conserved, tightly-controlled, and essential LPS molecule also 
frequently undergoes structural remodeling1–34. A prominent site within LPS for this 
dichotomy of conservation and variation is the lipid A domain, which is consistently 
synthesized as a hexa-acylated, bis-phosphorylated glucosamine disaccharide (Fig. 3.1), 
but can later be modified in various ways that promote bacterial survival in harsh 
environments and within the mammalian host24. One aspect of lipid A production that has 
particularly rigid constancy within an organism is the length of each acyl chain of this 
hydrophobic anchor4. However, understanding the contribution of acyl chain length to 
membrane properties has been impeded by the difficulty in engineering the essential lipid 
A biosynthetic enzymes and by the confounding modifications that can occur to lipid A, 
post-synthesis. 
Within a species, the arrangement and length of the acyl chains are consistent in 
each lipid A molecule, and in Escherichia coli, each acyl chain is 14 carbons in length 
with the exception of the secondary acyl chain at the C2ʹ′-position, which is 12 carbons 
long3,5678 (Fig 3.1). Likewise, each organism encodes enzymes with specific carbon rulers, 
but these vary among species and range from a specificity for acyl chains that are 10 
carbons in length up to 27 in some organisms9. The biosynthetic enzymes responsible for 
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acyl chain addition to lipid A maintain specificity by the precise length of their 
hydrophobic fatty acyl pocket, or carbon ruler6,74. Although these enzymes generate 
homogeneous lipid A within each cell, the size of the carbon ruler, and thus the length of 
the acyl chains of lipid A, differ between organisms4,9. The essential nature of the first 8 
of 9 enzymatic steps of lipid A biosynthesis (Fig. 1.2) have made engineering the length 
of acyl chains within a particular organism difficult, although temperature sensitive point 
mutants in the primary acyltransferases have been generated to allow expression of some 
homologs from other organisms for enzyme characterization10,11. 
One of the principal difficulties in comparing organisms that produce lipid A with 
differing acyl chain length is the confounding effects of extensive modification that 
occurs elsewhere on the lipid A molecule post-synthesis, but differs among species. 
Because lipid A forms the outer leaflet of the outer membrane and anchors the 
polysaccharide tail of LPS to the cell surface, its integrity is crucial to protrude toxic 
molecules from the bacterial cell. Even slight modifications to its structure can enhance 
or compromise survival in a harsh extracellular environment. Loss, gain, or decoration of 
acyl chains can increase or decrease resistance to antimicrobial compounds up to 100-
fold12–14.  The charged phosphate groups of lipid A can be masked, modified, or removed, 
limiting the negative charge of the cell surface and altering the association of cationic 
antimicrobial peptides151617. Modifications such as these have been shown to affect the 
normally robust permeability barrier to many compounds such as detergents and many 
antibiotics, including aminoglycosides, macrolides, penicillins, polypeptides, 
glycopeptides131819. Prior work on the effect of lipid A acyl chain length to the 
permeability barrier is limited, but a temperature sensitive mutant of the primary 
acyltransferase, lpxA, was complemented with the homolog from Neisseria meningiditis, 
which resulted in a C12 at the 3 and 3ʹ′-position primary acyl chains instead of the typical 
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C14. The shortened chains caused an increase in susceptibility to novobiocin, 
erythromycin, rifampicin, and bacitracin11. Whether the secondary acyl chains of lipid A 
have similar results has not been systematically studied. 
Lipid A structure is also crucial for detection and control of Gram-negative 
infection by the host innate immune system. The lipid A domain of LPS triggers the toll-
like receptor 4/ myeloid differentiation factor 2 homodimer (TLR4/MD2), initiating 
inflammatory cytokine signaling pathways that ultimately lead to bacterial clearance. The 
acyl chains of lipid A fit snugly into the hydrophobic pocket of each unit of the MD2 
cofactor within the homodimer interact with the which associates with TLR4, and a 
homodimer forms. The hexa-acylated, bis-phosphorylated structure of wild type E. coli 
lipid A (Fig 3.1a) is thought to be the ideal structure for maximal induction of 
TLR4/MD2 signaling, and removing acyl chains of lipid A decreases TLR4/MD2 
activation20,21. In fact, remodeling lipid A after its synthesis affords many Gram-negative 
pathogens evasion of host TLR4/MD2 detection2. The length of lipid A acyl chains are 
generally speculated as important for proper insertion into MD2, but direct comparison 
between strains of the same background with altered acyl chain length has been limited, 
and data respecting altered secondary acyl chains is completely lacking.  
Previous studies have initiated understanding of this question. Inactivating the 
cold-shock secondary palmitoleate (C16:1)-transferase, LpxP, in cold conditions causes a 
10-fold decrease in minimum inhibitory concentration (MIC) to rifampicin and 
vancomycin, but not to other antibiotics tested22. However, this fatty acyl chain is 
unsaturated and likely alters various membrane properties to adapt to cold environments, 
such as membrane fluidity23. Other studies have altered the lengths of various acyl chains 
of lipid A and observed slight TLR4/MD2 activation phenotypes, but these studies have 
either used synthetic mimetics that vary structurally from lipid A and do not include 
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longer acyl chains24, or lipid A samples that differ in multiple aspects of lipid A structure, 
making direct conclusions problematic. Some of these studies have also used only murine 
cell lines, but human and murine TLR4 differ greatly in their lipid A substrate 
specificity2520,26. One study did compare B. pertussis lipid A from isogenic strains altered 
only in the length of a single primary acyl chain and found increasing the length from 
C10 or C12 to a C14 caused a modest increase in human TLR4/MD2 activity27.  
Lipid A biosynthesis is tightly-regulated and well-conserved. In attempt to 
elucidate the benefits the particular lengths of secondary acyl chains E. coli lipid A, we 
have generated two sets of strains that range from 12-16 carbons in length at either the 
C2ʹ′- or C3ʹ′-position secondary acyl chains (Fig. 3.1b,c, 1.2)). Additionally, we have 
generated a strain in which the secondary acyl chain lengths are reversed compared to 
wild type (Fig 3.1d). Overall, stronger phenotypes were observed in membrane 
permeability than in TLR4/MD2 activation, indicating that the evolution of the acyl chain 
specificity of lipid A acyltransferases might have a stronger selective pressure for 
maintaining barrier integrity, while other lipid A modifications are sufficient to aid in 
evasion of the host immune response. 
3.2 RESULTS 
3.2.1  Altering the lengths of the secondary acyl chains on E. coli lipid A. 
In order to generate two sets of strains that varied in length at either the 2ʹ′- or 3ʹ′-
position secondary acyl chain, we replaced the genes encoding the E. coli acyltransferase 
enzymes LpxM and LpxL with heterologously expressed homologs (Fig. 1.2). The lpxM 
gene is nonessential, but lpxL mutants can only survive very slow growth on minimal 
media at low temperatures without compensatory expression of another copy of lpxL or 
one of its homologs5,8.  
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Figure 3.1  Lipid A from E. coli with varying lengths of secondary acyl chains.  
(a) The structure of wild type E. coli lipid A. (b) Lipid A from engineered strains with 
varying lengths (C12-C16) of the 3′-position secondary acyl chain transferred onto the 
molecule by LpxM. (c) Lipid A from engineered strains with varying lengths (C12-C16) 
of the 2′-secondary acyl chain transferred onto the molecule by LpxL. (d) Structure of 
engineered lipid A with the lengths of the 3′- and 2′-position secondary acyl chains 
reversed compared to wild type.  
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First, a clean template strain was generated from the W3110 parent by deleting 
the genes encoding the lipid A modification enzymes EptA and LpxT, which transfer a 
phosphoethanolamine and a phosphate group onto the 1-position phosphate of lipid A 
(Fig. 1.1d, 2.2a)17,28,29. This strain expresses the native E. coli lpxL and lpxM 
acyltransferase genes and produces a homogeneous lipid A profile with a C12 secondary 
acyl chain at the 2ʹ′-position and a C14 secondary acyl chain at the 3ʹ′-position, and is thus 
referred to as L12M14 in this work (Fig. 3.1).  
Further genetic manipulation of the L12M14 strain allowed alteration of the 
length of the secondary acyl chain added by LpxM at the 3ʹ′-position of lipid A. LpxM 
was deleted and recombinant lpxM genes could be expressed from the IPTG inducible 
plasmid, pQLinkN. Lipid A from the organisms Yersinia pestis and Campylobacter jejuni 
contain acyl chains at this position with lengths of C12 and C16, respectively30,31. In 
attempt to generate a strain with a laurate (C12) at this position, the lpxM homolog of 
Yersinia pestis (YPO2063) was expressed to generate the strain referred to as L12M12. 
Likewise, the gene responsible for acylation at the 3ʹ′-secondary position in C. jejuni, 
known as lpxJ (Cjj81176_0482) in this organism due to sequence divergence31, was 
expressed from the plasmid to transfer a palmitoyl (C16) acyl chain onto lipid A and 
yield the strain L12M16.  
To evaluate the lipid A in strains which differ only in the length of the C2ʹ′-
position secondary acyl chain transferred by LpxL, the strains L14M14 and L16M14 
were generated. Because LpxL is essential in rich broth at 37° C, lpxL homologs were 
heterologously expressed introduced into the L12M14 strain before deletion of the E. coli 
lpxL gene. Vibrio cholerae lipid A contains a C14 at the C2ʹ′-position and thus the lpxL  
gene (Vc0213) was chosen for expression to generate the L14M14 E. coli strain32. 
Increased expression of the E. coli LpxM was necessary in the L14M14 strain for 
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complete acylation, so the plasmid pACYC expressing LpxMEC was also introduced. To 
generate strains with longer secondary acyl chains at the C2ʹ′-position, lpxL equivalents 
from C. jejuni33 and Helicobacter pylori34 were expressed in strain L12M14 and the E. 
coli lpxL gene was deleted. C. jejuni and H. pylori lipid A contain a palmitoyl (C16) and 
stearoyl (C18) chain at this site, respectively, but when expressed in E. coli, we found 
that the H. pylori enzyme transferred primarily a C16 chain onto lipid A. We expect this 
is largely due to the shorter-chain pool of acyl-acyl carrier protein (acyl-ACP) donor 
substrate present in E. coli compared to H. pylori. Although H. pylori lpxL activity has 
previously been observed in E. coli, the length of acyl chain was not investigated34. 
Because the H. pylori LpxL enzyme was more efficient in E. coli than the C. jejuni LpxL, 
the strain containing the H. pylori LpxL was used for all further experiments and is 
designated L16M14. The expected lengths of chains and host organisms of these 
enzymes are summarized in the strain table (Table 5.2). Strains were tested for growth 
and all strains reached similar maximum yields to the wild type parent, W3110 and the 
template strain with wild type lipid A, L12M14. However, strain L14M14 had an 
increased lag phase. This could be due to the additional presence of the pACYC plasmid 
in this strain (Fig. 3.2). 
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Figure 3.2  Growth curve of strains engineered for altered secondary acyl chain length of 
lipid A.  
All strains were grown in LB at 37° C in the appropriate antibiotics and the OD600 was 
measured every 30 minutes. Most strains grew indistinguishable to wild type. Strain 
L14M14 displays an extended lag time and slightly lower maximal growth. 
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3.2.2  Analysis of lipid A profiles of acyl-engineered strains. 
Consistent production of homogeneous lipid A containing altered secondary acyl 
chain length was confirmed by thin layer chromatography (TLC) and MALDI-TOF mass 
spectrometry (MS) for each strain. For TLC analysis, bacteria were grown in the presence 
of radioactive phosphate (32Pi) and the lipid A was purified, separated, and visualized to 
verify successful incorporation of both secondary acyl chains onto the lipid A. This 
method is highly quantitative and illustrates the homogeneity of each hexa-acylated, bis-
phosphorylated lipid A profile (Fig 3.3). Not surprisingly, the incremental lengthening of 
the acyl chains does not drastically alter the migration of lipid A on the plate. 
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Figure 3.3  Thin layer chromatography (TLC) of 32Pi-labeled lipid A from acyl-
engineered strains.  
All strains were grown in the presence of 32Pi and purified lipid A samples were separated 
by TLC. Lipid A from the wild type parent strain, W3110 is used as a migration control 
for hexa-acylated, bis-phosphorylated lipid A. Acyl chain mutants are also each 
compared to the template strain, L12M14, which is lacking lipid A modification enzyme 
LpxT, responsible for the slower migrating, phosphorylated lipid A species present in 
W3110 but absent in acyl-engineered strains. All strains, whether acyl chain length was 
altered at the 3ʹ′- (a) or 2ʹ′-position (b) secondary acyl chain, or both (c) demonstrated a 
homogeneous lipid A profile of hexa-acylated lipid A. Altering acyl chain length did not 
seem to affect migration of lipid A on the plate.  
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In order to identify the length of acyl chains in each strain and confirm the 
relative purity of each strain, mass spectrometry was performed. Analysis of strain 
L12M12 (Fig. 3.4a) results in a major peak with an m/z of 1769.7, which is consistent 
with lipid A containing a C12 at the secondary 3ʹ′-position. The predominant peak in 
strain L12M14 (Fig. 3.4b) at 1797.2 m/z is consistent with wild type lipid A chain length, 
and illustrates the expected mass increase of 27 m/z according to the addition of a single 
acyl chain that is two carbons longer than in lipid A from the L12M12 strain. Similarly, 
in the L12M16 strain, a major peak at m/z of 1824.2 is observed (Fig. 3.4c).    
MS analysis of the strains with a range of lengths at the 2ʹ′-position secondary acyl 
chain also resulted in peaks consistent with expected masses. Fig 3.4d and 3.4e indicate 
major peaks at m/z 1824.1 and 1853.1 for the L14M14 and L16M14 strains, respectively. 
These masses correspond to lipid A molecules with the expected length of acyl chains 
and confirm the transfer of acyl chains by the heterologously expressed enzymes. 
Analysis of strain L14M12 resulted in spectra quite similar to the template strain 
L12M14, as expected. The V. cholerae LpxL and Y. pestis LpxM were found to be quite 
specific in adding a C14 or C12, respectively, and we expect that these enzymes maintain 
their site-specificity in the L12M14 chain. 
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Figure 3.4  MS analysis of acyl-engineered lipid A from E. coli.  
Lipid was purified from strains with engineered secondary acyl chain length and analyzed 
by negative ion MALDI/TOF mass spectrometry. (a-c) MS analysis of lipid A from 
strains varying in length at the 3ʹ′-position secondary acyl chain. (d and e) MS analysis of 
lipid A isolated from strains varying in length at the 2ʹ′-position secondary acyl chain. (f) 
MS analysis of strain L14M12 with the lengths of secondary acyl chains reversed 
compared to wild type lipid A. 
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3.2.3  TLR4 activation by whole cells and purified LPS from strains varying in 
secondary acyl chain length on lipid A. 
It is well established that changes to the number and the arrangement of the acyl 
chains on lipid A have drastic effects on activation of the mammalian host receptor 
complex, TLR4/MD2 and the subsequent induction of cytokine signaling. The degree 
that lipid A fits snugly into the pocket of MD2 has a great effect on TLR4 activation. 
TLR4 antagonists with only four acyl chains, eritoran and lipid IVA, fit deeper into the 
MD-2 pocket than hexa-acylated species, which limits the interactions between the lipid 
A substrate molecule and the two TLR4 dimers35. It is conceivable that lengthening or 
shortening the acyl chains of lipid A could have a similar effect, but the contribution of 
the length of acyl chains to this lipid A-MD2/TLR4 interaction has not been 
systematically studied.   
 To investigate the effect of altering the secondary acyl chains of lipid A on TLR4 
activation, whole bacterial cells from each engineered strain were incubated with a 
human embryonic kidney (HEK) reporter cell line that secretes alkaline phosphatase 
upon TLR4 activation and signaling. Short chain lipid A could potentially fit deeper into 
the pocket of MD2, which could help or hinder association between the TLR4/MD2/lipid 
A homodimer. Similarly, long chain lipid A could impede sufficient insertion into the 
MD2 pocket and partially disrupt the complex. However, we were surprised to find that 
TLR4 assays resulted in quite similar activation curves for each strain (Fig. 3.5). At low 
cell densities (102-105), longer secondary acyl chains at the 2ʹ′-position (Strains L14M14 
and L16M14) resulted in a modest decrease in TLR4 stimulation, and a shorter secondary 
acyl chain at the 3ʹ′-position (strain L12M12) slightly increased activation. However, at 
high cell densities, all the strains are as agonistic as wild type lipid A. Rearranging the 
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acyl chains in the L12M14 and the L14M12 strains also had little effect on TLR4 
activation. 
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Figure 3.5  TLR4/MD2 activation by whole bacteria cells with varying lengths of 
secondary acyl chains. 
Increasing cell numbers were incubated with HEK293 cells expressing human TLR4 and 
its cofactors MD2 and CD14 and a reporter alkaline phosphatase system for detection of 
activation of TLR4 signaling. Non-stimulatory, penta-acylated strain BN5 was used as a 
negative control. Top panel, strains varying in acyl chain length at the 3ʹ′-position 
secondary acyl chain are compared to each other and BN5. Bottom panel, strains varying 
in acyl chain length at the 2ʹ′-position secondary acyl chain as well as the strain with 
reversed length of secondary acyl chains are compared to each other and BN5. A p-value 
of <0.05 at any given concentration relative to the L12M14 strain is indicated by an 
asterisk. 
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A similar phenomenon occurred when purified LPS from each strain was 
incubated with the HEK-TLR4 reporter cells. At low LPS concentrations (0.01-1ng/ml), 
the presence of the C16 acyl chain caused a slight decrease in TLR4 activation, with a 
stronger effect when this chain was in the 2ʹ′-position. However, at high LPS 
concentrations (10-100 ng/ml shown, up to 10 ug/ml tested), each sample was 
indistinguishable (Fig. 3.6). When using LPS from the L12M14 and L14M12 strains in 
which the secondary acyl chain lengths are reversed, no difference in TLR4 activation 
was seen (Fig 3.6, bottom). Although modest effects on TLR4 activation were observed 
at low doses of cells and LPS, the overall effect of altering the length of secondary acyl 
chains of lipid A is quite minimal. 
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Figure 3.6  TLR4/MD2 activation by purified LPS from strains with varying lengths of 
secondary acyl chains. 
Increasing concentrations of LPS were incubated with HEK293 cells expressing human 
TLR4 and its cofactors MD2 and CD14 and a reporter alkaline phosphatase system for 
detection of activation of TLR4 signaling. LPS from unstimulatory, penta-acylated strain 
BN5 was used as a negative control. Top panel, activation by LPS from strains varying in 
acyl chain length at the 3ʹ′-position secondary acyl chain are compared to each other and 
BN5. Middle panel, activation by LPS from strains varying in acyl chain length at the 2ʹ′-
position secondary acyl chain are compared to each other and BN5. Bottom panel, 
activation by LPS from the strain with reversed arrangement of secondary acyl chains is 
compared to LPS from wild type secondary acyl chain length and BN5. A p-value of 
<0.05 at any given concentration relative to the L12M14 strain is indicated by an asterisk. 
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3.2.4  Analysis of the outer membrane permeability barrier in strains with acyl-
engineered lipid A. 
Gram-negative bacteria tightly control the lengths of each acyl chain incorporated 
into their lipid A. However, among species, variation exists in these length specificities. 
Since the effect on TLR4 signaling appears to be minimal, we investigated the membrane 
properties of the strains with varying length of secondary acyl chains and found that E. 
coli may have evolved specificity in lipid A acyl chain length that is crucial to maintain a 
robust permeability barrier.  
To test the outer membrane permeability barrier, we grew each strain (at least 
three biological replicates done in duplicate) in LB and various membrane stressors and 
small molecules designed to probe for membrane permeability as follows: bile salts (Fig. 
3.7), ethylenediaminetetraacetic acid (EDTA) (Fig. 3.8), sodium dodecyl sulfate (SDS) 
(Fig. 3.9), and vancomycin (Fig. 3.10).   
As an enteric organism, E. coli is well-adapted to resist high concentrations of membrane 
perturbing agents found in the gastrointestinal tract like bile and similar compounds, such 
as SDS36. Gram-negative bacteria are also naturally resistant to some antimicrobials that 
swiftly eliminate Gram-positive pathogens, such as vancomycin37. EDTA, a metal 
chelator, disturbs the cationic bridges that stabilize charges between the negative 
phosphate groups of lipid A38. Various mechanisms contribute to survival in such 
environments, but resistance is largely due to the outer membrane’s effectiveness at 
protruding such molecules.  
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Figure 3.7  Growth of acyl-engineered strains in the presence of bile.  
Growth of all strains including the W3110 parent and the penta-acylated LpxM mutant 
(BN5) was performed in LB in the presence of increasing concentrations of bile for 12 
hrs and the OD600 was measured. The top panel represents growth of strains modified 
only at the 3ʹ′-position secondary acyl chain transferred onto lipid A by LpxM. The 
middle panel shows results for the 2ʹ′-position secondary acyl chain transferred onto lipid 
A by LpxL. The bottom panel represents growth of the strain with both secondary acyl 
chains reversed compared to wild type. A p-value of <0.05 relative to the L12M14 strain 
at 20 mg/ml is indicated by an asterisk in the legend. 
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Figure 3.8  Growth of acyl-engineered strains in the presence of SDS.  
Growth of all strains including the W3110 parent and the penta-acylated lpxM mutant 
(BN5) was performed in LB in the presence of increasing concentrations of SDS for 12 
hrs and the OD600 was measured. The top panel represents growth of strains modified 
only at the 3ʹ′-position secondary acyl chain transferred onto lipid A by LpxM. The 
middle panel shows results for the 2ʹ′-position secondary acyl chain transferred onto lipid 
A by LpxL. The bottom panel represents growth of the strain with both secondary acyl 
chains reversed compared to wild type. A p-value of <0.05 relative to the L12M14 strain 
at 30 mg/ml is indicated by an asterisk in the legend. 
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Figure 3.9  Growth of acyl-engineered strains in the presence of EDTA.  
Growth of all strains including the W3110 parent and the penta-acylated LpxM mutant 
(BN5) was performed in LB in the presence of increasing concentrations of EDTA for 12 
hrs and the OD600 was measured. The top panel represents growth of strains modified 
only at the 3ʹ′-position secondary acyl chain transferred onto lipid A by LpxM. The 
middle panel shows results for the 2ʹ′-position secondary acyl chain transferred onto lipid 
A by LpxL. The bottom panel represents growth of the strain with both secondary acyl 
chains reversed compared to wild type. A p-value of <0.05 relative to the L12M14 strain 
at 6 mg/ml is indicated by an asterisk in the legend.  
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Figure 3.10  Growth of acyl-engineered strains in the presence of vancomycin.  
Growth of all strains including the W3110 parent and the penta-acylated LpxM mutant 
(BN5) was performed in LB in the presence of increasing concentrations of vancomycin 
for 12 hrs and the OD600 was measured. The top panel represents growth of strains 
modified only at the 3ʹ′-position secondary acyl chain transferred onto lipid A by LpxM. 
The middle panel shows results for the 2ʹ′-position secondary acyl chain transferred onto 
lipid A by LpxL. The bottom panel represents growth of the strain with both secondary 
acyl chains reversed compared to wild type. A p-value of <0.05 relative to the L12M14 
strain at 400 ug/ml is indicated by an asterisk in the legend. 
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In all conditions tested, strain L12M14 with wild type secondary acyl chain length 
grew similarly to the parent strain, W3110. Strain L12M12, with a shorter secondary acyl 
chain at the LpxM position grew like wild type in vancomycin and EDTA, but was 
severely compromised in bile and SDS. When that same secondary acyl chain was 
lengthened to a C16 in strain L12M16, low intermediate growth in SDS and vancomycin 
occurred, but drastic sensitivity to EDTA and bile were observed. 
Altering the acyl chain at the LpxL position also affected growth in the various 
compounds. Strain L14M14 was sensitive to all compounds tested but strain L16M14 
grew at high intermediate levels in bile, SDS, and EDTA, although it was sensitive to 
vancomycin.   
When strain L14M12 with reversed secondary acyl chain length was compared to 
the L12M14 strain with wild type acyl chains, high sensitivity to vancomycin and SDS 
was observed, but growth in EDTA and bile was observed to be similar to the wild type 
strain.  
 
3.3 DISCUSSION 
Gram-negative bacteria frequently modify the lipid A covering the cell surface to 
adapt to the diverse environments they encounter. However, acyl chain length of lipid A 
remains quite consistent amidst the addition or removal of various types of chemical 
groups from the molecule. In some cases, like removal of an entire acyl chain, these 
diverse modifications aid the bacteria in evasion of the innate immune response by 
decreasing stimulation of the TLR4/MD2 host LPS receptor394. Other modifications, such 
as masking the charge of the phosphate groups of lipid A with an amine-containing 
moiety, primarily benefit the bacterium by limiting association of antimicrobial 
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molecules like CAMPS to the cell surface17. The work described herein investigated how 
the specific lengths of the secondary acyl chains of E. coli lipid A affect initiating host 
immune detection by TLR4/MD2 and resistance to compounds that perturb the outer 
membrane permeability barrier.  
To study these aspects of lipid A in a controlled system with no other variations in 
lipid A structure, we have generated two sets of strains with altered length at the 2ʹ′-
position secondary acyl chain incorporated by the acyltransferase LpxL (Fig. 3.1b) or the 
3ʹ′-position secondary acyl chain transferred onto the molecule by the acyltransferase 
LpxM (Fig. 3.1c). Additionally, we generated a strain in which the lengths of the 
secondary acyl chains are reversed in the two positions, relative to wild type (Fig 3.1d). 
In spite of the general idea in the field that acyl chain length plays a significant role in 
TLR4 activation, varying the secondary acyl chains of lipid A from C12 to C16 had little 
effect on activity. When the HEK reporter cell line was incubated with low bacterial cell 
numbers or low concentrations of LPS from each strain, a shorter acyl chain (C12) at the 
LpxM position slightly increased activation, while longer acyl chains (C14 and C16) at 
the LpxL position slightly decreased it. However, at high concentrations of both cells and 
purified LPS, the lipid A with any of the lengths of secondary acyl chains was maximally 
stimulatory. 
Upon investigating the growth of each acyl-engineered strain in the presence of 
compounds that perturb the membrane or are normally excluded from the cell in Gram-
negative bacteria, it was apparent that secondary acyl chain length was crucial for proper 
integrity of the cell surface. Altering the length of either the 2ʹ′- and 3ʹ′-position secondary 
acyl chains affected bacterial fitness in bile, EDTA, SDS, and vancomycin. Apparently, 
E. coli has evolved precise acyltransferase enzymes in order to establish a perfect 
harmony of acyl chain length it its membranes. While acyl chain length is tightly 
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regulated and consistent within a species, it can differ greatly between organisms. It is 
likely that each have an intricate balance between the barrier qualities of the lipids and 
proteins that comprise their membranes. 
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Chapter 4:  Conclusion3 
4.1 IMPORTANCE FOR THE CONTINUED STUDY OF LIPID A  
4.1.1  Lipid A vaccine adjuvants and therapeutics. 
A wide variety of lipid A modifications equip Gram-negative bacteria for survival 
in their respective niches in the host and other environments. The lipid A molecule as 
well as the many biosynthetic and modification enzymes that have evolved provide a tool 
kit for potential immune system modulation in therapeutics. In this work, we have studied 
the range of lipid A modifications that can be made to acyl chain number and 
arrangement in combination with the loss of one or both phosphate groups. Our hope is 
that some of these combinatorial strains will prove useful for vaccine development. We 
have also generated strains modified in acyl chain length, which apparently do not 
modulate the immune system, but do offer insight into bacterial fitness. All of these 
strains provide a unique resource for future studies involving endotoxin, the outer 
membrane, and Gram-negative bacteria. 
4.1.2  Effects on other cellular processes. 
A better understanding of how lipid A biosynthetic and modification enzymes 
affect lipid A, the outer membrane, and pathogenesis will also greatly contribute to 
efforts for the control of infectious disease. For example, functions of lipid A are 
highlighted by the interplay of lipid A modifications with a diverse set of cellular 
processes and both of these facets of lipid A biology emphasize the importance for a 
continued effort to understand the regulation, benefits and host response to lipid A in its 
numerous modified forms. Recent studies have revealed links between lipid A 
                                                
3 Large portions of this chapter have been previously published. Needham, B. D. & Trent, M. S. Fortifying 
the barrier: the impact of lipid A remodelling on bacterial pathogenesis. Nat. Rev. Microbiol. 11, 467–481 
(2013). 
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modifications and diverse processes within the bacterial cell. These associations support 
the notion that lipid A modifications are crucial for bacterial pathogenesis and survival.  
4.1.2.1 Multitarget lipid A modification enzymes 
In Campylobacter jejuni, the enzyme EptC modifies both lipid A and a structural 
protein required for flagellar assembly.  EptC is a homologue of E.coli EptA and both 
enzymes transfer a phosphoethanolamine residue to the 1ʹ′- and 4ʹ′-positions of lipid A 
(see Table 1), masking both phosphate groups and promoting CAMP resistance.  
Interestingly, in C. jejuni EptC also transfers an essential phosphoethanolamine to FlgG 
(a flagellar rod protein135) and EptC mutants lack wild type motility and produce fewer 
flagella, which is required for virulence. This promiscuous enzyme also modifies 
carbohydrates of the C. jejuni LOS core and glycosylated proteins136. 
4.1.2.2 Recycling of biosynthetic intermediates 
During the assembly of bacterial polymers (for example, peptidoglycan, the 
capsule and LPS) a wide array of glycoconjugates must be trafficked across the inner 
membrane137.  These glycan intermediates are assembled on a universal carrier lipid 
known as undecaprenyl-phosphate (C55-P)138.  The C55-P transports the glycan precursors 
in a pyrophosphate linkage (C55-PP-precursor) and when the glycan is removed, the lipid 
is released as a pyrophosphate and requires dephosphorylation for the carrier to be 
recycled138.  Within the periplasm, LpxT transfers a secondary phosphate group onto lipid 
A at the 1-position (Fig. 4.1C) and uses the C55-PP as a donor105. This finding represented 
a novel and unexpected link between the modification of lipid A and the recycling of C55-
PP.  Furthermore, the connection between these systems revealed that C55-PP could serve 
as a high energy phosphate donor for various periplasmic components, although these 
potential targets are largely unidentified. 
 83 
4.1.2.3 Outer membrane protein activation 
As a membrane component, LPS is more than just a platform for activities at the 
cell surface139.  It also has a role in the activation of a class of proteases that are 
widespread among Gram-negative enteric bacteria, known as omptins.  The activity of 
one member of this class (OmpT protease) has been evaluated in the presence of hexa-
acylated and tri-acylated lipid A, and was found to be only active in the presence of hexa-
acylated lipid A140. Interestingly, another omptin named plasminogen (Pla), which is 
central to Y. pestis pathogenesis, is more active in Y. pestis grown at 37° C and producing 
tetra-acylated lipid A, compared to cells grown at 20° C and producing hexa-acylated 
lipid A141. 
4.1.2.4 Outer membrane vesicles and toxin delivery 
Modifications of lipid A also affect the delivery of proteins and toxins that are 
associated with the outer membrane and outer membrane vesicles (OMVs).  In organisms 
such as Porphyromonas gingivalis and P. aeruginosa, negatively charged LPS is 
enriched in OMVs142,143. Furthermore, in P. gingivalis the lipid A found in OMVs is more 
deacylated compared to the lipid A that is present in whole cell membranes, suggesting 
that lipid A modification could facilitate vesicle formation or the sorting of outer 
membrane proteins that are packaged into vesicles143. In P. aeruginosa, OMV formation 
is stimulated by a small signalling molecule, Pseudomonas Quinolone Signal (PQS), 
which is packaged into vesicles and induces vesicle formation in P. aeruginosa cells as 
well as other bacteria144. The exact mechanism of OMV formation is not understood; 
however, PQS was found to interact with the 4ʹ′-phosphate group and acyl chains of lipid 
A, indicating that modification of lipid A could influence the efficiency of vesicle 
shedding145.  
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The structure of lipid A and the Kdo residues of LPS also affect the delivery of 
toxins.  For example, two similar toxins - cholera toxin (CT) produced by V. cholerae and 
heat-labile toxin (LT) produced by Enterotoxigenic E. coli (ETEC) - are both secreted, 
are structurally similar and bind the same host cell receptor. However, CT causes a more 
severe diarrheal disease146. Although the topic is controversial147, the difference in toxin 
severity seems to be due to the partial sequestration of LT as it binds to Kdo-lipid A on 
the bacterial cell surface after secretion. By contrast the Kdo sugar attached to lipid A in 
V. cholerae is phosphorylated by the kinase KdkA (Table 1.1), and this modification 
inhibits CT association with the outer membrane, thereby allowing robust toxin 
secretion148.  
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Figure 4.1  Networks between lipid A modifications and other cellular processes 
Depicted here are examples of the variety of networks between lipid A modification 
enzymes and various other virulence factors and functions in the cell. Connections with 
outer membrane vesicle (OMV) formation, toxin secretion and delivery, motility, 
recycling of undecaprenyl pyrophosphate (C55-PP), and activation of outer membrane 
proteins (OMP) have been identified. 
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4.2 FUTURE QUESTIONS TO BE ADDRESSED IN THE LIPID A FIELD  
In spite of the continual progress studying the Gram-negative outer membrane 
and its components, many questions remain unanswered. The continued development of 
animal models is paramount to more closely mimic the host infection site. Considerable 
progress has been made in this regard by the recent generation of a transgenic mouse 
expressing the human TLR4 receptor149 There is much to learn about how lipid A and its 
modifications affect the outcome of polymicrobial infections, with recent studies 
suggesting that LPS has an important role within such communities. For instance, 
purified LPS from intestinal commensal bacteria has been found to promote replication 
and transmission of viruses150,151. Pathogenesis of orally acquired poliovirus, which 
replicates in the intestine before spreading to cause a severe systemic infection, is 
supported by the intestinal microbiota and purified LPS151. Mouse mammary tumor virus 
(MMTV) manipulates the innate immune response by binding LPS and eliciting TLR4-
dependent production of interleukin-10, a cytokine that is required for MMTV 
persistence150. Although these viruses bind LPS and this enhances infectivity in vitro, 
how lipid A modifications affect these phenomena is currently unknown.  
Improved methods for studying lipid A modifications in vivo could also help 
elucidate any potential links between modified lipid A and diseases involving TLR4, 
such as inflammatory bowel disease, diabetes, rheumatoid arthritis and atherosclerosis152.  
Important insights into human TLR4 polymorphisms might now be possible using the 
humanized mouse model149; and it should also be possible to examine how different 
variants of TLR4 affect susceptibility to infection by organisms with modified lipid A. 
This could potentially lead to more personalized medical treatment through the 
development of a new range of modified TLR4 agonists that could serve as customized 
immunomodulatory agents to induce or repress particular cytokine responses.  
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It remains a mystery why lipid A is essential in virtually all Gram-negative 
organisms. Furthermore, why lipid A biosynthesis is well-conserved only to have 
complex modifications occur later, sometimes constitutively, is not understood. How the 
modification enzymes are distributed and organized within the membrane is also unclear. 
For example, it is not known whether lipid rafts exist in bacteria and if some or all of the 
modification enzymes are enriched at these sites. Lipid A molecules with certain 
modifications could also be specifically localized in the membrane. Such an organization 
could have a major influence on the activation of key outer membrane proteins or OMV 
formation and protein sorting.  
With further study, inhibitors of modification enzymes could be developed for use 
as antibiotics or in combination with currently used antibiotics. Although immense 
progress has been made in our understanding of lipid A modification systems in Gram-
negative bacteria and their importance for pathogenesis, there is much work yet to be 
done.  
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Chapter 5: Experimental Procedures 
 
5.1 CONSTRUCTION OF MUTANT STRAINS 
5.1.1  Mutants generated in Chapter 2. 
Construction of mutant strains was performed by P1 vir phage transduction using 
Keio mutants, as previously described105.  BN1 was generated by deletion of pagP from 
BN0, an lpxT and eptA double mutant8,35.  Deletion of all three genes resulted in a strain 
producing >95% of the prototypical, hexa-acylated bis-phosphorylated lipid A species.  
To double the potential lipid A profiles that one set of enzymes could yield, BN2 was 
generated by removal of the KanR cassette and deletion of lpxM from BN1.  Strains were 
confirmed by PCR, 32Pi radiolabeling, and MS153 (Table 5.1 for strains and plasmids).  
5.2.2  Mutants generated in Chapter 3. 
Gene deletions of eptA, lpxT, and lpxM35,154 and subsequent removal of each 
antibiotic cassette155 were performed by P1 vir phage transduction using Keio mutants, as 
previously described. Mutation of lpxL was performed using P1 vir phage transduction 
using the previously described mutant MKV15B122. LpxL mutation was only performed 
after introduction of a covering pQLinkN plasmid expressing an lpxL homolog (see Table 
5.2 for plasmids). The plasmids encoding lpxM homologs were transformed into strain 
BN5. To generate strain L14M12, the pQ-LVCMYP plasmid was introduced into the BN5 
strain followed by deletion of lpxL using MKV15B phage. Strains were confirmed by 
PCR, 32Pi radiolabeling, and MS. 
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Table 5.1 Bacterial strains and plasmids used for chapter 2. 
 
 
Strain or 
plasmid 
 
 
Genotype or description 
 
Source or reference 
Strains   
W3110 Wild type, F- l- rph-1 INV(rrnD, rrnE)1 rph-1 E. coli Genetic Stock 
center (Yale) 
MLK1067 W3110 lpxM::Ωcam 156 
CMR300 W3110 (kdtA::kan) pWMsbA 157 
BN0 W3110 ΔeptA, ΔlpxT This work 
BN1 BN0 ΔpagP This work 
BN2 BN1 ΔlpxM::kan This work 
 
Plasmids 
 
  
pQLinkN Vector containing a tac promotor, Ampr 106 
pE pQLinkN containing lpxE This work 
pF pQLinkN containing lpxF This work 
pL pQLinkN containing pagL This work 
pO pQLinkN containing lpxO This work 
pP pQLinkN containing pagP This work 
pR pQLinkN containing lpxR This work 
pEF pQLinkN containing lpxE, lpxF This work 
pEL pQLinkN containing lpxE, pagL This work 
pEO pQLinkN containing lpxE, lpxO This work 
pEP pQLinkN containing lpxE, pagP This work 
pER pQLinkN containing lpxE, lpxR This work 
pFL pQLinkN containing lpxF, pagL This work 
pFP pQLinkN containing lpxF, pagP This work 
pFR pQLinkN containing lpxF. lpxR This work 
pLO pQLinkN containing pagL, lpxO This work 
pLP pQLinkN containing pagL, pagP This work 
pLR pQLinkN containing pagL, lpxR This work 
pOP pQLinkN containing lpxO, pagP This work 
pOR pQLinkN containing lpxO, lpxR This work 
pPR pQLinkN containing pagP, lpxR This work 
pEFL pQLinkN containing lpxE, lpxF, pagL This work 
pEFP pQLinkN containing lpxE, lpxF, pagP This work 
pEFR pQLinkN containing lpxE, lpxF, lpxR This work 
pELO pQLinkN containing lpxE, pagL, lpxO This work 
pELP pQLinkN containing lpxE, pagL, pagP This work 
pELR pQLinkN containing lpxE, pagL, lpxR This work 
pEOP pQLinkN containing lpxE, lpxO, pagP This work 
pEPR pQLinkN containing lpxE, pagP, lpxR This work 
pFLP pQLinkN containing lpxR, pagL, pagP This work 
pFLR pQLinkN containing lpxF, pagL, lpxR This work 
pFPR pQLinkN containing lpxF, pagP, lpxR This work 
pLOP pQLinkN containing pagL, lpxO, pagP This work 
pLOR pQLinkN containing pagL, lpxO, lpxR This work 
pLPR pQLinkN containing pagL, pagP, lpxR This work 
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Table 5.1 continued. 
pOPR pQLinkN containing lpxO, pagP, lpxR This work 
pEFLP pQLinkN containing lpxE, lpxF, pagL, pagP This work 
pEFLR pQLinkN containing lpxE. lpxF, pagL, lpxR This work 
pEFPR pQLinkN containing lpxE, lpxF, pagP, lpxR This work 
pELOP pQLinkN containing lpxE. pagL, lpxO, pagP This work 
pELOR pQLinkN containing lpxE. pagL, lpxO, lpxR This work 
pELPR pQLinkN containing lpxE, pagL, pagP, lpxR This work 
pEOPR pQLinkN containing lpxE, lpxO, pagP, lpxR This work 
pFLPR pQLinkN containing lpxF. pagL, pagP, lpxR This work 
pLOPR pQLinkN containing pagL, lpxO, pagP, lpxR This work 
 
Table 5.2 Bacterial strains and plasmids used for chapter 3. 
 
 
Strain or 
plasmid 
 
 
Genotype or description 
 
Source or reference 
Strains   
W3110 Wild type, F- l- rph-1 INV(rrnD, rrnE)1 rph-1 E. coli Genetic Stock 
center (Yale) 
BN5 W3110 ΔeptA, ΔlpxT, ΔlpxM::kan 156 
L12M12 BN5 pQ-MYP This work 
L12M14 W3110 ΔeptA, ΔlpxT This work 
L12M16 BN5 pQ-MCJ This work 
L14M14 L12M14 LpxL::tet pQ-MVC This work 
L16M14 L12M14 LpxL::tet pQ-MCJ This work 
L14M12 BN5 LpxL::tet pQ-LVCMYP This work 
 
Plasmids 
  
pQLinkN Vector containing a tac promotor, Ampr 106 
pACYC-MEC pACYC-LpxMEC This work 
pQ-LCJ pQLinkN containing lpxL from C. jejuni This work 
pQ-LVC pQLinkN containing lpxL from V. cholerae This work 
pQ-MYP pQLinkN containing lpxM from Y. pestis This work 
pQ-MCJ pQLinkN containing lpxM from C. jejuni This work 
pQ-MHP pQLinkN containing lpxM from H. pylori This work 
pQ-LVCMYP pQLinkN containing lpxL from V. cholerae and lpxM 
from Y. pestis 
This work 
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5.2 PLASMID CONSTRUCTION AND GROWTH CONDITIONS 
5.2.1  Plasmids and growth conditions of strains generated in Chapter 2. 
Six genes, lpxE, lpxF, lpxO, lpxR, pagL, and pagP, were cloned into pQLinkN, as 
previously described106.  Transformation of BN1 and BN2 with the plasmids yielded the 
61 strains in chapter 2.  All strains were grown at 37° C in Luria-Bertani Broth (LB) 
supplemented with 100 μg/ml ampicillin where appropriate and 50 μM to 1 mM IPTG 
with an optimized isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration between 
50 μM and 1 mM, as determined by TLC analysis of enzyme activity.   
5.2.1  Plasmids and growth conditions of strains generated in Chapter 3. 
The lpxM genes from Y. pestis (GENE NAME) and C. jejuni (GENE NAME) and 
the lpxL genes from V. cholerae (GENE NAME), C. jejuni(GENE NAME), and H. 
pylori(GENE NAME) were cloned separately into the pQLinkN plasmid using standard 
cloning strategy. A combinatorial plasmid expressing lpxL from V. cholerae and lpxM 
from Y. pestis was generated as previously described. LpxM from E. coli was inserted 
into the tetracycline cassette of pACYC using standard techniques. See supplementary 
Table X for a full list of plasmids generated in this study. 
All strains were grown at 37° C in LB supplemented with 100ug/ml ampicillin, 
30ug/ml and 200 uM isopropyl β-D-1-thiogalactopyranoside (IPTG) where appropriate.  
5.3 ISOLATION OF LIPID A   
32Pi radiolabeled lipid A was isolated from 7 ml cultures for analysis by TLC as 
previously described153158. For MS, lipid A was prepared from 15 ml cultures158,159 and 
analyzed using a MALDI-TOF/TOF (ABI 4700 Proteomics Analyzer) mass spectrometer 
in the negative ion linear mode as previously described158. 
 92 
5.4 TLR SIGNALING ASSAYS 
The HEK-BlueTM hTLR4, HEK-BlueTM hTLR2, and THP1-XBlue™-MD2-CD14 
cell lines were purchased from Invivogen and maintained according to their 
specifications. Whole cell aliquots and LPS samples were serial diluted for assays as 
previously described77,159. At least two biological replicates were each done in triplicate 
and one representative set was shown here. 
5.5 ISOLATION AND QUANTIFICATION OF LPS.   
LPS was isolated from all strains by phenol extraction and purified by the 
Hirschfeld method as previously described158,159. Quantification was achieved using the 3-
deoxy-D-manno-octulosonic acid (Kdo) colorimetric assay160 to normalize the samples to 
0.5 mg/ml using E. coli K12 LPS (LPS EK-Ultrapure, Invivogen) as a standard. 
5.6 WHOLE CELL BACTERIAL SAMPLE PREPARATION   
Cells for assays were prepared by growing a diluted overnight culture to an 
OD600 of 1.0 and washing with sterile phosphate buffered saline (PBS) to remove lysed 
cells or vesicle fragments. Cell pellets were gently resuspended in 5 mls of PBS, and the 
OD600 was measured. 5 x 109 cells were harvested by centrifugation, gently resuspended 
in 1 ml PBS and aliquoted for storage at -80° C. CFU plating after storage at -80° C 
confirmed equivalent cell counts between samples. 
5.7 LIPOPOLYSACCHARIDE STIMULATION ASSAYS WITH THP-1 CELLS AND CYTOKINE 
ANALYSIS   
THP-1 human monocytes (ATCC) were maintained according to ATCC’s 
specifications. THP-1 monocytes were differentiated into macrophages and stimulated for 
24 h with 100 ng/ml LPS as previously described161.  LPS samples were quantified as 
described above and normalized to the number of LPS molecules.  Culture supernatants 
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from triplicate wells were harvested and sent to Ocean Ridge Biosciences (Palm Beach 
Gardens, FL) for Luminex quantification of the cytokines: TNF-α, IL-1β, IL-6, IL-8, G-
CSF, RANTES and MCP-1.  
5.8 PURIFICATION OF INDIVIDUAL LIPID A SPECIES  
Purification of 3-O-deacyl-4ʹ′-monophosphoryl lipid A produced by strain 
BN1/pELP was performed by reverse-phase chromatography as described previously162 
with ~ 0.4-0.6 mg of the target lipid obtained per liter of culture.  The amount of purified 
lipid A was quantified by phosphate determination as previously described163.  Based 
upon TLC analysis, approximately 1/3rd of the lipid A synthesized is 3-O-deacyl-4ʹ′-
monophosphoryl lipid A. Assuming there are 109 CFU/ml of bacteria at an OD600 of 1.0 
and ~106 lipid A molecules per cell8, the maximum yield of the target lipid would be ~1 
mg/L of culture.   
5.9 MOUSE IGG AND CYTOKINE QUANTIFICATION   
All procedures were performed according to IACUC and institutional guidelines.  
Monophosphoryl lipid A (MPLA) was purchased from Invivogen and is referred to as 
MPL, for simplicity.  Female Balb/cJ mice (Jackson) (7 mice/group), 6-8 weeks old, were 
bled from the tail vein (~20 µl) prior to primary injection (day -1) and on day 28.  Serum 
was stored at -20° C for further analysis. Emulsions were prepared as described 
previously164, and on day 1 mice were immunized subcutaneously into the backpad with 
50 µl of an emulsion of 30 ug lysozyme from chicken egg white (HEL) with 6 pM of 
purified lipid A, determined by phosphate quantification as previously described163.  
Secondary and final immunizations were performed intraperitoneally on day 21 and day 
35, respectively, with 50 µl of the same emulsions.  On day 36, serum was collected by 
heart puncture for Luminex cytokine analysis. 
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Serum IgG titers were determined by ELISA serial dilution.  Serum dilutions 
from 1/200 through 1/437000 were captured on HEL coated high binding ELISA plates 
(Corning Costar 3590) and detected with 1/5000 anti-Mouse IgG HRP (Jackson Immuno, 
115-065-209). Plates were analyzed with GraphPad Prism software and titers were 
determined as the point where the non-linear fitted curve determined 3-fold signal above 
background. 
5.10 BACTERIAL GROWTH IN THE PRESENCE OF ANTIBIOTICS AND MEMBRANE 
STRESSORS   
Growth assays were performed in LB broth at 37° C in a 96-well plate format. 
Each well contained 150 ul of inoculum at OD600 0.05 containing increasing 
concentrations of one of the following compounds at the levels described in the figures: 
ethylenediaminetetraacetic acid (EDTA) (Fisher), bile salts (Sigma), sodium dodecyl 
sulfate (SDS) (Fisher), and Vancomycin (Fisher). 
5.12 STATISTICAL ANALYSIS   
Statistical analysis was performed using one-tailed T-tests. P-values were 
calculated with an n≥3, α=0.05 or 0.01, as reported in the for TLR, THP-1, and 
membrane susceptibility assays. Error bars on graphs refer to standard deviation. 
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Appendices 
Appendix A. Mass spectrometry results for all strains used in chapter 2. 
All spectra, excluding the 3 examples presented in the main text, can be found in 
this figure. Lipid A structures corresponding to the mass peak are depicted by cartoons 
next to the peak. Peak clusters at m/z ~1375 correspond to phospholipid contamination, 
confirmed by TLC isolation of the species. The labile 1-phosphate can be lost, resulting 
in a mass difference of ~ 80 mass units. a,b) Negative ion mode MS of BN1 and BN2 
strains, respectively, confirmed the activity of the enzymes expressed in combinations. A 
minor species of penta-acylated lipid A can be observed in some enzyme combinations, 
corresponding to a peak at m/z ~1585. c) Positive ion mode MS was done for all strains 
expressing both phosphatases, LpxE and LpxF.  Positive mode often results in single or 
double sodium adducts on the molecules, resulting in peak masses that are ~23 or 46 
mass units higher than the exact mass of each structure.  
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Group A. BN1 strains. 
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Group A continued. BN1 strains. 
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Group A continued. BN1 strains.
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Group A continued. BN1 strains.
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Group A continued. BN1 strains.
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Group A continued. BN1 strains.
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Group A continued. BN1 strains.
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Group A continued. BN1 strains.
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Group B. BN2 strains.
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Group B continued. BN2 strains.
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Group B continued. BN2 strains.
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Group B continued. BN2 strains.
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Group B continued. BN2 strains.
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Group B continued. BN2 strains.
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Group C. Positive mode analysis.
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Group C continued. Positive mode analysis.
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Appendix B. Quantitative data represented colorimetrically in Fig. 2.6 
All TLR4 data used to generate the colorimetric scale presented in Figure 2c is 
graphed here.  Significance is indicated by an asterisk and the p-values for samples that 
are significantly different from the BN1 background strain are denoted. a) TLR4 
stimulation is shown of all strains in the BN1 background.  These are split into three 
graphs due to number of samples. b) TLR4 stimulation is shown of all strains in the BN2 
background, split into three graphs due to number of samples. c) TLR4 stimulation with 
LPS is shown. 
 
Group A. BN1 strains. 
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Group A continued. BN1 strains. 
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Group A continued. BN1 strains. 
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Group B. BN2 strains. 
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Group B continued. BN2 strains.
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Group B continued. BN2 strains.
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Group C. LPS stimulation.
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